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ABSTRACT
Functional Evaluation of Cytochrome P450 2D6 Allelic Isoforms

Weiyan Zhang
Human CYP2D6 is one of the most important human P450s based on the number of
its drug substrates. It shows an extensive genetic polymorphism that influences its
expression and function. There are more than 80 different CYP2D6 alleles and allelic
variants that have been identified in human. However, only a part of alleles have been
characterized with respect to enzyme activity and substrate specificity. In the first project,
three alleles CYP2D6*24 (I297L), CYP2D6*27 (E410K) and CYP2D6*26 (I369T) were
constructed and expressed. The enzymatic activities were evaluated by the metabolic rates
for dextromethorphan O-demethylation and N-demethylation; codeine O-demethylation
and N-demethylation. For DXM O-demethylation, CYP2D6*24 has the highest intrinsic
clearance value, as estimated by Vmax/Km ratio, followed by *1, *26 and *27; For DXM
N-demethylation, three allelic variants showed almost the same intrinsic clearance values
as the wild type CYP2D6. For codeine O-demethylation, 2D6*26 and *27 have the same
intrinsic clearance, it is around 2-fold higher than 2D6*1 as estimated by Vmax/Km ratio.
For codeine N-demethylation, the variant CYP2D6*26 exhibited higher enzyme efficiency
for codeine O-demethylation than codeine N-demethylation compared to the wild type and
other alleles.
The human CYP2D subfamily includes CYP2D6, CYP2D7 and CYP2D8P, which
locate at the CYP2D locus of chromosome 22. It was found that alternatively splicing of
CYP2D pre-mRNA could occur and these splicing variants are tissue-specific. However, it
is still unknown whether and how these alternatively splicing variants play important
physiological or pathological roles in these tissues. In the second project, a human brain
CYP2D7 variant was successfully constructed and expressed. However, the expressed
protein does not have enzymatic activity of P450 based on CO-reduce activity when the
heme was used as an iron source. Interestingly, the expressed protein restored the activity
when ∆-ALA, a precursor of heme, was used as an iron source. Metabolism studies show
that this CYP2D7 variant is capable of metabolizing codeine and probably tyramine but
not MPTP.
CYP2D6 polymorphism has been associated with various human cancer susceptibilities
such as lung, breast, skin and prostate cancers. It has hypothesized that the existence of these
alternatively splicing variants may impact the expression and functions of CYP2D6 in
extrahepatic tissues, and the alternation of CYP2D6 might play an important role in
determining cancer risk. However, the genotypes and function of these extrahepatic
CYP2D6 are still unknown. In the third project, several alternatively splicing variants
derived from different human tissues including liver, brain, skin, eye and prostate have been
cloned and sequenced. Among these variants, a full-length skin variant were constructed and
expressed. The results indicated that this variant can only express a 27 kD truncated protein
due to a deletion 91 bp in exon 6, which terminates the translation of C-terminus. So far,
several alternative splicing CYP2D variants have been identified in the different tissues of
human. Except for a brain CYP2D7 variant, none of them have been shown to be functional.
Nevertheless, the existence of these variants might cause the posttranscriptional downregulation of the expression of CYP2D6, and further influence the physiological or
pathological functions of CYP2D6 in these tissues.
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Chapter I

Genetic Polymorphism of P450 CYP2D6 and its Clinical Significance

I.

Overview

CYP2D6 is one of the most important human P450s based on the number of its drug
substrates, which include more than 50 commonly used drugs (13). It shows a very high
degree of inter-individual variability, which is primarily due to the extensive genetic
polymorphism that influences its expression and function (20). There are more than 80
different CYP2D6 alleles and allelic variants that have been identified (57). Genetic
polymorphism has been linked to four classes of phenotype based on the extent of drug
metabolism: “Poor Metabolizers” (PM) phenotypes are characterized by their failure to
use CYP2D6-dependent metabolic pathway for drug elimination, which affect up to 20%
of all clinically used drugs (39, 61); “Ultrarapid Metabolizers” (UM) phenotype can be
caused by alleles carrying multiple gene copies (57); “Intermediate Metabolizers” (IM)
phenotypes are severely deficient in their metabolism capacity compared to normal
“Extensive Metabolizers” (EM) since they express a low amount of residual activity due
to the presence of at least one partially deficient allele compared to PMs (21, 61).
Different capacity in metabolism of drugs can lead to severe toxicity or therapeutic
failure by altering the relation between dose and blood concentration of
pharmacologically active drug or metabolite (31). Individual difference in the expression
of CYP2D6 is reportedly a factor related to the susceptibility of cancer and other diseases

1

where environmental chemicals are implicated (35,37,40,50,118). For example, defects in
CYP2D6 have been associated with a number of CNS diseases such as Parkinson’s
disease (69, 90, 103, 106, 109) and the polymorphism of CYP2D6 is likely associated
with genetic susceptibility to melanoma (110).

The human CYP2D subfamily includes CYP2D6, CYP2D7 and CYP2D8P, which
locate at the CYP2D locus of chromosome 22 (43, 64). It was found that alternative
splicing of CYP2D pre-mRNA could occur and these splicing variants are tissue-specific
(52, 53). It is still unknown whether and how these alternative splicing variants play roles
in these tissues in terms of physiological and pathological functions.

II.

CYP2D6 Genetic Polymorphism and Alternative Splicing

(a). Overview: The CYP2D6 polymorphism, which was first discovered in the
genetic deficiency of debrisoquine and sparteine metabolism (75, 80), was shown to
affect the metabolism of a variety of structurally different drugs such as metoprolol and
bufuralol (24, 74). CYP2D6 polymorphism exhibits pronounced interethnic variation.
While initial observation and studies focused on Caucasian population (8), later on the
same phenomenon was also observed in other populations such as African-American,
Chinese and Japanese (7, 48, 108). The nomenclature homepage (http://www.
imm.ki.se/CYPalleles/) currently lists 44 alleles with a total number of currently 78
distinct alleles.
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The CYP2D6 polymorphism has been linked to four classes of phenotypes
including EM, PM, IM and UM. CYP2D6 polymorphism has high clinical significance,
e.g., difference in drug metabolism can lead to severe toxicity and therapeutic failure by
changing the relation between the dose and blood concentration. Thus, knowledge of an
individual’s CYP2D6 status can provide a rational approach to drug prescription.

(b). Null alleles: Null alleles were determined by the loss of enzymatic activity,
which cause the PM phenotype only if they present in homozygous or compound
heterozygous constellations. So far, there are about 20 different null alleles that have
been identified (http://www.imm.ki.se/CYPalleles/). These null alleles are caused by the
following factors: site mutations, insertion and deletion mutations or a deletion of the
larger chromosome that contains the entire CYP2D6 locus. Among those null alleles,
most alleles have single base pair mutations or small insertion/deletions that interrupt the
reading frame or that interfere with correct splicing, leading ultimately to prematurely
terminated protein products (29, 111, 126). These alleles include CYP2D6*3, *4, *6, *8,
*11, *15, *19, *20, *38, *40, *42, and *44. Only few alleles code for full-length but
nonfunctional proteins (2D6*7; 2D6*12, *14, *18) (34) . There are at least three alleles
caused by a large chromosomal deletion resulting in deletion of the entire CYP2D6 gene
(2D6*5) (39) or by the interruption of open reading frame caused by the splice of
CYP2D6/2D7 (2D6*13 and 2D6*16) (22, 23). Among those null alleles, CYP2D6*4 is
the most frequent null allele identified in Caucasians (60, 102). It occurs with an allele
frequency of about 20 to 25% and it is responsible for 70 to 90% of all PMs.
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(c). Alleles associated with decreased enzyme activity: Alleles associated with
decreased enzyme activity include CYP2D6*2, *9, *10, *17, *36, *41 (http://www.imm.
ki.se/CYPalleles). These alleles were characterized with IM phenotypes (94). For
CYP2D6*2, a mutation was identified in the promoter region of CYP2D6 (- 1584 C > G).
In a family study, the CYP2D6*2 [-1584G] allele co-segregated with the EM phenotype
for sparteine, whereas *2 [-1584C] co-segregated with the IM phenotype (94). Thus, the
allele 2D*2 [-1584C] was renamed 2D6*41. The frequency of 2D6*41 in the entire
population is approximately 8% and the *41genotype allows to identify more than 50%
of all IM in Caucasians. CYP2D6*9 was characterized initially in a family with IM
phenotypes. Although this allele lacks codon 281(∆K281), it still shows enzymatic activity
(114). This allele exhibits a frequency of about 1 to 2% in Caucasians (60, 102) . The
C100T mutation leading to Pro34Ser is a functionally dominant mutation in 2D6*10 and
probably also in *36 and *37. Pro34 is part of a proline-rich region that is highly
conserved between the hydrophobic membrane anchor and the globular heme-binding
portion of the enzyme (84, 122). In Caucasians, the 2D6*10 allele has a frequency of
about 2% and accounts for 10 to 20% of individuals with IM phenotype (46, 101). The
2D6*1 allele has two non-synonymous substitutions: one is the mutation identified in
2D6*2 and the other mutation is T107I, which results in a decrease of activity (84). This
allele is practically absent from European Caucasians, but it is predominantly present in
African or African -American populations with a frequency of about 30% (46).

(d). Alleles with increased enzyme activity: Ultra-rapid metabolism is caused by
occurrence of duplicated, multi-duplicated or amplified CYP2D6 genes. The 2D6xN
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alleles (N including *1, *2, *35, *41) were shown to occur with allele frequencies of
approximately 1 to 2% in northern European populations (5, 18, 46, 101), whereas much
higher frequencies were observed in Ethiopians and Saudi Arabians (3, 84). An
intermediate frequency was found in Spanish populations (2). In human liver, a
significantly elevated level of CYP2D6 protein and enzymatic activity was described
with 2D6*1/*2x2 genotype.

(e). CYP2D alternative splicing: The human CYP2D genes are located on
chromosome 22q13.1. The CYP2D subfamily includes CYP2D6 and two related genes,
CYP2D7 and CYP2D8P at its locus. These three genes display 92%-97% similarities with
each other across their introns and exons. Each CYP2D gene consists of 9 exons and 8
introns. CYP2D8P is a pseudogene with multiple deletions and insertions that disrupts the
open reading frame. The CYP2D7 gene is more similar to CYP2D6 than to CYP2D8P. Its
coding sequence contains an insertion (T138) mutation in the first exon, which causes a
frame shift mutation and premature translation termination (43, 64). Alternative splicing
of these genes has been detected in human liver, lung, brain and breast tissues
(44,45,52,53,121). Such alternative splicing could regulate the expression of CYP2D6
and result in different CYP2D variants. These variants include a (intron 5 included); b
(intron 6 included); b’ (3’ portion of exon 6 deleted); c (exon 6 deleted); d (3’ 57-bp
portion of intron 6 included); e (3’ portion of exon 6 deleted, 3’ 57-bp potion of intron 6
included). Variant c was derived from CYP2D6, variants d, e, and b derived from
CYP2D7, and variant b’ derived from both CYP2D6 and CYP2D7. An alternatively
spliced functional transcript of CYP2D7 containing a partial inclusion of intron 6 was
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recently reported in human brain but not in liver or kidney from the same individual.
Further study indicated that this brain variant CYP2D7 is functional, and it can
metabolize codeine to morphine with greater efficiency compared to CYP2D6 (88).

III.

CYP2D6 Substrates

(a). Substrates metabolized by CYP2D6: Although CYP2D6 substrates are
structurally diverse, they all contain a basic nitrogen atom that is involved in an
electrostatic interaction between the substrates and a negatively charged amino acid in the
substrate-binding site of the enzyme (42). Since the polymorphism of the enzyme results
in poor, intermediate, efficient or ultrarapid metabolizers of CYP2D6 drugs, Kirchheiner
et al. provided approximate dose adjustments according to the CYP2D6 phenotype as
based on the meta-analysis (65). The following table shows the drugs metabolized by
CYP2D6 and clinical consequences for the PM, IM, EM and UM phenotypes (56).

Therapeutic class

Pathway catalyzed

Drug

by CYP2D6

Codeine

O-demethylation

Dextromethorphan

O-demethylation

Dihydrocodeine

O-demethylation

Analgesica/antitussives Ethylmorphine

Anti-ADHD drug

O-deethylation

Hydrocodone

N-demethylation

Norcodeine

O-demethylation

Oxycodone

O-demethylation

Atomoxetine

Aromatic
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PM IM EM UM

Therapeutic class

Pathway catalyzed

Drug

by CYP2D6

PM IM EM UM

hydroxylation
Aromatic

Aprindine

hydroxylation

Encainide

O-demethylation

Flecainide

O-dealkylation (?)
Aromatic

Mexiletine

Antiarrhythmics

hydroxylation

N-propylajmaline

oxidation
Aromatic

Propafenone

hydroxylation
Aliphatic

Sparteine

Tricyclic
antidepressants

hydroxylation
Arylamine N-

Procainamide

Antidementia drugs

Benzylic

hydroxylation

Galanthamine

O-demethylation

Nicergoline

N-demethylation
Benzylic

Amitriptyline

70

90

105 135

60

85

112 145

40

76

117 165

30

75

130 180

hydroxylation
Aromatic

Clomipramine

hydroxylation
Aromatic

Desipramine

hydroxylation
Aromatic

Imipramine

hydroxylation
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Therapeutic class

Pathway catalyzed

Drug

by CYP2D6
Benzylic

Nortriptyline

PM IM EM UM
48

90

115 155

hydroxylation

Citalopram

N-demethylation

Desmethylcitalopram N-demethylation

Other antidepressants

Fluoxetine

N-demethylation

Fluvoxamine

unclear

Maprotiline

unclear

35

77

120 170

Aromatic

70

87

110 135

Mianserin

hydroxylation
Aromatic

Minaprine

hydroxylation
Aromatic

Mirtazapine

hydroxylation

Paroxetine

Demethylenation

65

90

108 143

Venlafaxine

O-demethylation

68

85

105 130

Antidiabetic

Phenformine

Antiestrogen

Tamoxifen

Aromatic
hydroxylation
Aromatic
hydroxylation
Benzylic

Debrisoquine

Antihypertensives

hydroxylation
Aromatic

Guanoxan

hydroxylation
Aromatic

Indoramin

hydroxylation
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Therapeutic class

Pathway catalyzed

Drug

by CYP2D6
Aromatic

Dolasetron

Antiemetics

hydroxylation
Aromatic

Ondansetron

hydroxylation
Aromatic

Tropisetron

hydroxylation
Aromatic

Mequitazine

Hydroxylation

Antihistamines

Aromatic

Promethazine

Antipsychotics

Appetite suppressant
Beta adrenergic
blocking agents

PM IM EM UM

hydroxylation

Haloperidol

N-dealkylation

67

90

108 126

Perphenazine

N-dealkylation

30

80

130 170

Aliphatic

Risperidone

hydroxylation

Thioridazine

Sulfoxidation

37

82

127 165

Zuclopenthixol

N-dealkylation

55

85

115 142

Dexfenfluramine

N-dealkylation
Aromatic

Alprenolol

hydroxylation
Benzylic

Bufuralol

hydroxylation
Aromatic

Bunitrolol

hydroxylation
Aromatic

Bupranolol

hydroxylation

9

Therapeutic class

Pathway catalyzed

Drug

by CYP2D6
Aromatic

Carvedilol

hydroxylation
Aliphatic

Metoprolol

hydroxylation
Aromatic

Propranolol

hydroxylation

Timolol
Calcium antagonist

MAO-inhibitors

Recreational drugs

PM IM EM UM

O-dealkylation
Aliphatic

Perhexiline

hydroxylation

Amiflamine

N-demethylation

Brofaromine

O-demethylation

Methoxyamphetamine O-demethylation
MDMA, MDME

Demethylenation
Aromatic

Cinnarizine

hydroxylation

Vasodilatators

Aromatic

Flunarizine

hydroxylation

(b). Inhibition and induction: Quinidine is the most potent inhibitor of CYP2D6
(107). Fluoxetine (9, 10, 58), paroxetine (58), and propofenone (68) are also potent
inhibitors of CYP2D6 with inhibition constant in the low nanomolar range. In contrast to
other members of CYP enzymes, CYP2D6 is not affected by classic enzyme inducers
such as phenobarbitone (30). Rifampicin treatment has given only 30% increase in
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clearance of sparteine, but metabolic ration was not significantly changed (30). About
33% reduction in the metabolic ratio of debrisoquine has been observed in female EM
using contraceptives (62) . During the menstrual cycle, insignificant decrease in
debrisoquine metabolic ration was observed during the luteal phase compared to
preovulatory phase (63). Heavy cigarette smoking and ovariectomy induced this enzyme
activity but only to a minor extent (73). In contrast, there is evidence that pregnancy has a
profound influence on CYP2D6 activity. Marked increase in metabolism of metoprolol
(51) and dextromethorphan has been reported during pregnancy (117).

(c). Protein structures and the specificity of substrates: Although the crystal
structure of CYP2D6 has not been solved, its structure has been modeled based on the
crystal structure of bacterial soluble P450 enzymes such as P450 101 (p450cam), P450
102 (P450BM3) and P450 108 (P450terp) (25, 87). It was found that CYP2D6 contains
five β-sheets (β1 to β5) and ten α-helixes (B, B’, C, F, G, I, J, I’, K and L). The hemebinding domain locates between Residues 400 to 444. In addition, several functional
residues have been identified in terms of the drug-enzyme interaction. Residue Asp301
(I-helix, residues 292 –324) has been characterized as being involved in electrostatic
interactions with substrates on the basis of homology modeling and site-directed
mutagenesis (32). Residue Glu216 (F-helix, residues 205 -229) also plays an important
role in the binding of the basic nitrogen of CYP2D6 substrates (89). One recent study
indicated that Phe120, located on the B’-C loop, contributes to determining the specificity
of substrate oxidation by CYP2D6 (36). Thus, it will be important to take into account
the influential role of Phe120 in substrate orientation along with the roles of Glu216 and
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Asp301 in selecting basic nitrogen compounds for the future development of predictive
models of the specificity of CYP2D6.

IV.

Impacts of CYP2D6 Polymorphism on Drug Metabolism

The CYP2D6 PM phenotype is characterized clinically by an impressive deficiency
in formation of the relevant metabolites of affected substrate, which can result in either
drug toxicity or inefficacy. The reverse effects occur in the cases of UEM (76). The
polymorphism of CYP2D6 is clinically more significant for tricyclic antidepressants,
certain neuroleptics, antiarrhythmics, antihypertensives, ß-blockers and morphine
derivatives (83) . For tricyclic antidepressants, both PM and UEM phenotypes of
CYP2D6 are at risk of adverse reactions (31). PM individuals given standard doses of
these drugs will develop toxic plasma concentrations, potentially leading to unpleasant
side effects including dry mouth, sedation and tremor or in some cases life threatening
cardiotoxicity (76). In contrast, usage of CYP2D6 substrates to UEM individuals results
in therapeutic failure since plasma concentrations of active drug at standard doses will be
far too low to effect (19). The clinical presentation of UEM and PM patients are at times
similar, leading to confusion in understanding the basis of adverse drug reaction. Due to
the lack of dose individualization, patients may be subjected to recurrent depressive
episodes and may not respond to treatment. Patients requiring treatment with
antidepressant or antipsychotic substrates of CYP2D6 may begin the normal treatment
regimen. Because of the long half-life of these drugs, toxic drug concentrations may take
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5-7 weeks to develop. Therefore, it is suggested that the patients be phenotyped before
starting treatment with drugs mainly metabolized by CYP2D6 (76).

A recent study showed that, in patients prescribed with psychiatric drugs that are
metabolized by CYP2D6, adverse drug reactions were observed in patient with inherited
mutations inactivating CYP2D6 (120). A lack of CYP2D6 enzyme would be expected to
result in reduced drug therapy effectiveness in instances where the prodrugs requiring
activation by CYP2D6 are used. For example, the analgesic effect of tramadol is severely
reduced in PMs (92). Similarly, following administration of the prodrug codeine,
morphine could not be detected in the plasma of CYP2D6 PMs (91, 92, 113). On the
contrary, severe abdominal pain, a typical adverse effect of morphine, was observed in all
UEM treated with codeine (57). Moreover, codeine produced prolongation of the
orocaecal transit time only in EM subjects (86).

Due to the clinical importance of CYP2D6 polymorphism on drug metabolism, it may
be considered to identify the genotypes of patients before they receive drugs mainly
metabolized by CYP2D6. Recently, Pedro Dorado et al (28) developed a PCR-based
strategy for CYP2D6 genotyping. This genotyping method is based on extra long PCR
(XL-PCR) and PCR restriction fragment-length polymorphism (PCR-RFLP) method, it
provided a rapid, straightforward, and inexpensive identification of 90%-95% of CYP2D6
PM or UM genotypes in a clinical routine, independent of the individual’s ethnic group.
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V.

Extrahepatic Expression of CYP2D6 and its Clinical significance

CYP2D6 is predominantly expressed in human liver. However, CYP2D mRNA was
also detected in a variety of extrahepatic tissues such as brain, lung, skin and other tissues
using reverse transcription followed by PCR amplification (RT-PCR). Problems common
to all these investigations are the generally low expression levels, the occurrence of
differentially spliced transcripts, and the possible interference with the CYP2D7/8
pseudogene expression (33, 52). So far, only one functional CYP2D7 variant has been
reported in human brain. It is still unclear whether there are other types of functional
CYP2D expressed in other tissues. In addition, the functions of these tissue specific
CYP2D have not yet been investigated.

(a). Gastrointestinal tract: In the gastrointestinal tract, the expression of
cytochromes P450 and of other xenobiotic metabolizing enzymes is confined to the single
cell layer of the mucosal enterocytes (127). Their concentrations in homogenates of
intestinal tissue samples are therefore much lower as compared to liver. Nevertheless,
intracellular enterocytic expression levels may be as high as in hepatocytes. It has been
shown that a number of Phase I and phase II enzymes are expressed in the intestine with
CYP3A constituting the major P450 form (78). CYP2D6 was characterized at both
protein and enzyme activity level in human and rhesus monkey intestinal microsomes and
it was qualitatively similar to the liver enzyme (93). In addition, inter-individual
variability of CYP2D6 in human intestinal mucosa was at the low abundance and
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activity, its contribution to the first-pass effect of orally administered CYP2D6 substrates
was estimated to be minimal (79).

(b). Brain: Several lines of evidence have indicated that CYP2D genes are expressed
in human brain. First, cDNA cloning and Western blotting analyses indicated both
mRNA and protein of CYP2D are present in human brain (38, 115). Second, microsomal
preparations from human brain are capable of metabolizing dextromethorphan, a specific
substrate of CYP2D6 (116). Third, immunohistochemical analysis and in situ
hybridization of brain sections showed that expression of CYP2D is confined to certain
regions and distinct neuronal cell types throughout the human brain, including the
pigmented neurons of the substantia nigra (104). Finally, a functional CYP2D7 variant
was recently cloned from human brain but not in liver or kidney from the same
individual. This brain variant CYP2D7 is functional, and it can metabolize codeine to
morphine with greater efficiency compared to CYP2D6 (88).

The expression of CYP2D in the brain is of particular interest since CYP2D6 could
metabolize many centrally active drugs and endogenous substances (49, 82, 124, 125). In
addition, neurotoxin MPTP is potent inducer of Parkinson’s disease (38, 41). Recent
studies indicated that CYP2D6 is involved in the detoxification of MPTP, which implies
that CYP2D6 may be a susceptibility factor for Parkinsonism as initially suggested by
Barbeau et al (4). However, the link between CYP2D6 and Parkinson’s disease is
controversial. Phenotypic studies have failed to support the relationship between
CYP2D6 and Parkinson’s disease. The genetic studies initially indicated a link between
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CYP2D6B mutations and Parkinson’s disease (15, 71, 100), but critical analysis of the
literature and studies emerging from independent laboratories fail to confirm this (97).

Higher expression of CYP2D6 in brain was detected in alcoholics compared to nonalcoholics, possibly explaining altered sensitivity of alcoholics to centrally acting drugs
and to the mediation of neurotoxic and behavioral effects of alcohol (85). The possible
endogenous substrates of CYP2D6 in brain were recently investigated in a broad and
systematic way by Yu et al (86, 87). In two consecutive papers, the authors describe first
that 5-methoxytryptamine, a metabolite and precursor of melatonin, is a specific and high
turnover substrate of CYP2D6 that is being converted to serotonin. In the second article,
a systematic screen identified two related 5-methoxytryptamines as additional highaffinity, high-capacity, endogenous CYP2D6 substrates. The biological roles of these
substrates in the central nervous system are poorly understood (125). To explore the
significance of these findings for the control of mood, the origin of psychiatric disorders
or the development of personality traits are fascinating directions for future research.

(c). Skin: Several lines of evidence showed that CYP2D6 is most likely expressed in
human skin tissues as variants that may have specific roles with respect to the physiology
of normal skin and genesis of skin cancers (110). First, clinical studies indicated that
CYP2D6 was significantly associated with human skin cancers. Second, BLAST analysis
indicated that cDNA of CYP2D6 was present in the EST libraries from human skin
tissues (EST name 602634230F1). Third, the messenger RNA of CYP2D6 was found in
human skin tissues (123). These results suggest that CYP2D6 is probably expressed as a
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functional form in human skin tissues. However, the genotypes and functions of CYP2D6
in human skin are still unknown since a complete and functional CYP2D6 variant has not
yet been obtained.

Ultraviolet B radiation (UVB) is experimentally demonstrated to be the most
effective light to induce skin cancer in animals, and can cause DNA damage, particularly
cyclobutane pyrimidine dimers (CPDs) and photoproducts which induce mutation in the
epidermal cell, and further lead to the development of cancer cells (55). CYP2D6 has the
interesting potential to act in opposing biological ways: detoxifying certain lipophilic
ultraviolet radiation or activating them to carcinogenic forms (59). Therefore,
polymorphism of CYP2D6 is likely to be associated with genetic susceptibility to wide
variety of cancers, including melanoma.

There are three well documented inactivating polymorphism at CYP2D6: gene
deletion, a splice site mutation and a nucleotide deletion in the coding region (81, 121).
Wolf et al found that there was no significant difference in the frequency of PMs, but
they did observe a significant increase in mutant alleles in the melanoma cohort (119).
Strange et al found a significantly higher frequency of mutant alleles and PMs in the
melanoma cases. In contrast, Dolzan et al found that there was no increase in mutant
CYP2D6 alleles in melanoma cases, but rather a non-significantly lower frequency of
poor metabolizers in the melanoma cohort (27). These studies are contradictory to each
other, thus it is unclear whether CYP2D6 is related to the genesis of melanoma. Strange
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proposed that CYP2D6 was possibly involved in detoxifying potentially carcinogenic
compounds rather than activating certain carcinogens (110).

(d). Lung and other tissues: Data concerning expression of CYP2D6 in lung is still
controversial as it was only observed in one study (47) whereas others reported
undetectably low levels (66, 96). The interesting aspect about a possible pulmonary
expression of CYP2D6 is its potential contribution to the in situ activation of lung
carcinogens. However, definitive proof for the activation of procarcinogens by CYP2D6
is still lacking and association studies between the CYP2D6 polymorphism and lung
cancer risk have been controversial (11, 14, 99). CYP2D6 mRNA detected by RT-PCR in
blood mononuclear cells was reported to be correlated to the in vivo debrisoquine MR
(metabolic ratio), suggesting that it might serve as a surrogate marker for systemic drug
oxidation capacity (12).

CYP2D6 mRNA was also detected by RT-PCR in human breast and breast tumor
tissue (52). If mRNA is being translated into an active enzyme in breast tumors, the
enzyme may contribute to the local metabolism of tamoxifen (17, 26). A correlation
between the amount of mRNA and the in vivo phenotype for debrisoquine hydroxylation
was also reported for bladder mucosa and tumor tissue (98). CYP2D6 mRNA was
furthermore detected by RT-PCR in the right ventricular tissue of the heart where it may
contribute to the metabolism of β-blockers (112).
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VI.

CYP2D6 and Cancer Susceptibility

Cutaneous basal cell carcinomas (BCCs) are a major burden to health care agencies
worldwide. The cancer is the most common in Caucasians and the estimated lifetime risk
for a North American child born in 1994 is about 30% (16, 54, 67, 95). Several studies
have identified some relevant genes to BCCs, CYP2D6 is one of the relevant genes, with
homozygosity for wild-type alleles (CYP2D6 EM) being associated with BCC risk,
although the mechanism is unclear (72).

A significant proportion of human cancers are initiated by environmental chemicals
acting as carcinogens. Previous studies showed the relationship between polymorphic
CYP2D6 and human pulmonary carcinogenesis. They determined the frequency of PMs
and EMs of debrisoquine in Slovene population of healthy individuals (n=107), lung
cancer patients (n =200), and melanoma patients (n =121). They indicated that PM
individuals appear to be less susceptible to lung cancer than EM individuals (1, 27).
Other studies have also indicated that PM phenotype is associated with reduced cancer
susceptibility, including bladder (6), liver (105), kidney (77) and breast cancer (70). All
these findings suggested that there is an influence of genetic polymorphism of CYP2D6
on the susceptibility to cancers, possibly by detoxifying certain chemicals involved in the
pathogenesis of cancers or linkage to another cancer-causing gene. Further research may
allow the identification of risk factors and contribute towards understanding the
molecular mechanisms underlying the process of carcinogenesis.
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Abstract

CYP2D6 is one of the most important human cytochrome P450s. It is not only
involved in the metabolism of a variety of widely used therapeutic drugs, but also is
related to certain environment-induced diseases. CYP2D6 shows a very high degree of
inter-individual variation, primarily due to its extensive genetic polymorphism. Some
alleles and allelic variants of CYP2D6 have been identified in humans. Most alleles have
yet to be characterized with respect to enzyme activity and substrate specificity.

The objective of our current study is to determine the effects of CYP2D6 allelic
isoforms on enzyme activity and substrate specificity. To achieve these goals, four
alleles, CYP2D6*24 (encoding the amino acid change I297L), CYP2D6*27 (E410K),
CYP2D6*26 (I369T) and CYP2D6*33(A237S) were selected to test if the functional
consequences of allelic variation found in human CYP2D6 are substrate-dependent. The
genes encoding these allelic isoforms were created by site-directed mutagenesis and
further over-expressed in a baculovirus-mediated expression system. The activities of the
enzymes were evaluated based on the metabolic rates for dextromethorphan Odemethylation, codeine O-demethylation and dextromethorphan N-demethylation. For
DXM O-demethylation, 2D6.24 has the highest intrinsic clearance value, as estimated by
Vmax/Km ratio, followed by 2D6.1, .26 and .27; For codeine O-demethylation,
CYP2D6.26 and .27 have the same intrinsic clearance, they are around 2-fold higher than
wild type CYP2D6 based on Vmax/Km ratio. CYP2D6.24 exhibited lower enzyme
efficiency for codeine O-demethylation compared to the wild type CYP2D6 and the other
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allelic isoforms. For DXM N-demethylation, CYP2D6.26 and .27 show simple
Michaelis-Menten saturation kinetics, but CYP2D6.1 and .24 demonstrate atypical
kinetic profiles. Overall the enzymatic consequences of human CYP2D6 allelic variations
are substrate dependent. These date provide a solid basis for future epidemiological,
clinical as well as interethnic studies of the CYP2D6 polymorphism.

Introduction

Cytochrome P450 enzymes, a superfamily of heme proteins, are responsible for the
oxidative metabolism of a diverse range of xenobiotics and endobiotics (16-18).
CYP2D6, one of the first well characterized phase I enzymes, is involved in the oxidation
of over 40 commonly prescribed drugs such as antiarrhythmics, antihypertensives, blockers, opioids, antipsychotics and tricyclic antidepressants (7, 12, 13, 25, 37).
CYP2D6 is polymorphically expressed in the general population, with over 70 known
allelic variants (http://www.imm.ki.se/CYPalleles/ cyp2d6.htm). Individuals who take the
drugs that are mainly metabolized by CYP2D6 have greatly difference in the occurrence
of side effects, therapeutic efficiency and drug interactions (30, 47). CYP2D6 also
metabolizes certain neurotoxins (8, 11), endogenous substances (35, 38) and
environmental agents such as procarcinogens (4). As a consequence, the expression of
CYP2D6 is related to the susceptibility of some human diseases (11, 24, 52).
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CYP2D6 genetic polymorphism has been linked to four classes of phenotypes based
on the extent of drug metabolism. The “Poor Metabolizers” (PM) phenotype is
characterized by the inability to use CYP2D6-dependent metabolic pathways for drug
elimination, which affect up to 20% of all clinically used drugs. The “Ultrarapid
Metabolizers” (UM) phenotype can be caused by alleles carrying multiple gene copies.
“Intermediate Metabolizers” (IM) are severely deficient in their metabolism capacity
compared to normal “Extensive Metabolizers” (EM). In contrast to PM, IM express a low
amount of residual activity due to the presence of at least one partially deficient allele
(34). The difference in metabolism of drugs can lead to severe toxicity or therapeutic
failure by altering the relation between dose and blood concentration of
pharmacologically active drug or metabolite.

The human CYP2D genes are located on chromosome 22q13.1. CYP2D subfamily
includes CYP2D6 and two related genes CYP2D7 and CYP2D8P at the CYP2D locus.
The three CYP2D genes display 92%-97% nucleotide similarities with each other across
their introns and exons. CYP2D6 genes consist of 9 exons and 8 introns. CYP2D8P is a
pseudogene with multiple deletions and insertions. The CYP2D7 gene is more similar to
CYP2D6 than to CYP2D8P. Its coding sequence contains only a single insertion (T138)
mutation in the first exon, which causes a frame shift mutation resulting in the premature
translation termination (29). Alternative splicing of these genes has been detected in
human liver, lung, brain and breast tissues (12, 15, 23, 24, 52). Such alternative splicing
could regulate the expression of CYP2D6 protein and result in different CYP2D variants:
a (intron 5 included); b (intron 6 included); b’ (3’ portion of exon 6 deleted); c (exon 6
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deleted); d (3’ 57-bp portion of intron 6 included); e (3’ portion of exon 6 deleted, 3’ 57bp potion of intron 6 included) (23, 52). Variant c was derived from CYP2D6; variants d,
e, and b from CYP2D7; variant b’ from both CYP2D6 and CYP2D7. Recent study
indicated that an alternatively spliced functional transcript of CYP2D7 containing partial
inclusion of intron 6 was identified in human brain but not in liver or kidney from the
same individual. This brain variant CYP2D7 can metabolize codeine to morphine with
greater efficiency compared to the corresponding activity in cells expressing CYP2D6
(40).

Various CYP2D6 alleles including a point mutation or multiple mutations as well as
rearrangements of genes and pseudogenes of the CYP2D6 gene cluster on chromosome
have been associated with deficient, decreased or increased enzymatic activity (9, 27).
Among the over 70 alleles and allelic variants, some of the allelic isoforms such as
CYP2D6*2, *10 and *17 have been well studied. The correlation between the presence
of 2D6 allelic variants and decreased in vivo capacity for marker reactions was well
established (41, 43, 55). The enzyme efficiencies for the metabolism of each substrate
decreased in the order of 2d6.1 > 2d6.2 > 2d6.17 > 2d6.10 (54). In some cases, specific
ethnic populations appear to correspond with specific metabolize ranges. For example,
CYP2D6*2 is mainly present in Caucasian populations (42, 56); CYP2D6*10 is present
at a high frequency in Asia populations (6, 10, 45, 46, 55); CYP2D6*17 is commonly
present in African-Americans and Black Africans (1, 33, 36, 49, 51).
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In this study, we selected four CYP2D6 alleles, CYP2D6*33(A237),
CYP2D6*24(I297L), CYP2D6*26(I369T) and CYP2D6*27(E410K), to test the
hypothesis that the functional consequences of alleles found in human CYP2D6 are
substrate-dependent. The nucleotide substitutions and the combinations of predicted
amino acid changes of these alleles are listed in the web site maintained by M. Oscarson
(http:// www.imm.ki.se/CYPalleles/cyp2d6.htm). These alleles were constructed from
CYP2D6*1 cDNA and over-expressed in a baculovirus expression system. The
enzymatic activity of these allelic variations was evaluated by metabolizing two clinically
important drugs including dextromethorphan (DXM) and codeine. The results further
confirmed that the effects of these allelic variations on enzyme activity are substrate
dependent.

Materials and Methods
Bacterial strains, cell lines and culture conditions: Escherichia coli BMh 71-81
mutS strain (Clontech) was used for regular amplification of plasmids; E. coli XL1-Blue
supercompetent cell (Stratagene) was used to perform site-directed mutagenesis; E. coli
DH10BAC strain (Invitrogen) was used to construct and select recombinant bacmid DNA.
The E. coli BMH 71-81 mutS and DH10BAC strains were cultured in Luria Bertani
medium and XL1-Blue strain was cultured in NZY+ broth at 37˚C. The insect cell line T.
ni was used for infection of baculovirus and expression of recombinant proteins. The cell
line was cultured in SFX-INSECT medium (HyClone) containing 10% fetal bovine
serum at 27˚C. Penicillin-G (100 µg/ml), streptomycin sulfate (61µg/ml) and ampho-
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terecin-B (0.6 µg/ml) were routinely added to the medium to reduce contamination by
bacteria or fungi.

Chemicals: Dextromethorphan, dextrorphan, 3-methoxymorphinan, reduced
NADPH were purchased from Sigma/RBI (Natick, MA). Codeine, norcodeine, morphine,
trifluoroacetic acid (TFA), and 60% perchloric acid were purchased from Sigma-Aldrich
(St. Louis, MO). Methanol Orthophosphoric acid were purchased from Fischer Scientific.
Electrophoresis, immunoblotting and PCR conditions: Sodim dodecyl sulfatepolyacrylamide gel eletrophoresis (SDS-PAGE) was carried out as previously reported.
Monoclonal antibody against CYP2D6 was purchased from BD GeneTestTM. Westernblot assays were performed as previously described, using the Amersham ECL system.
For site-directed mutagenesis, the PCR condition is: 95˚C 1 minute for 1 cycle (predenature) followed by 95˚C 1 minute (denature), 55˚C 1 minute (annealing) and 65˚C 12
minutes (elongation) for total 30 cycles. For confirmation of recombinant bacmid DNA
and virus, the GeneAmp XL PCR Kit (Applied Biosystems) was used. The PCR
condition is: 94˚C 4 minute for 1 cycle followed by 94˚C 45 seconds, 55˚C 45 seconds
and 72˚C 5 minutes for total 35 cycles.

Site-directed mutagenesis and DNA sequencing: Human CYP2D6 cDNA was
obtained from F. Gonzalez (National Cancer Institute, National Institutes of Health,
Bethesda, MD) (Gonzalez et. al., 1988). This cDNA sequence was reverted to
CYP2D6*1(Yu et al., 2002), which was further subcloned into the plasmid pFastBac I
(Invitrogen) at the restriction endonuclease cut sites of Hind III/BamH I and resulted in
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the plasmid pFB2D6*1. The obtained plasmid were used as template to create these
alleles by using QuickChange Multi site-directed Mutagenesis Kit according to the
manufacture’s recommendation (Stratagene). The oligonucleotides for site-directed
mutagenesis were listed as the follows: A237S
5’CCCAGCGCTGTCTGGCAAGGTCC3’; I297L
5’GAACCTGCGCCTAGTGGTGGCTG3’; I369T 5’GCTTTGGGGACACCGTCCC
CCTGGG3’; E410K 5’GGCCGTCTGGAAGAAGCCCTTCC3’. The resultant constructs
pFB2D6*24 (I297L), pFB2D6*26 (I369T), pFB2D6*27 (E410K) and pFB2D6*33
(A237S) were confirmed by DNA sequencing analysis with the following primers: 2D6
(5’-GGATTATTCATA CCGTCC-3’); C82 (5’-CGCTGGGCTGCACGC-3’); C534 (5’GGACAAAGCCGTG AG-3’) and C1011 (5’-CGTGATAGGGCAGG-3’).

Construction of recombinant baculovirus: To create the recombinant baculovirus,
the above constructs were transformed into competent cell DH10BAC containing the
bacmid with mini-attTn7 target site and the help plasmid as manufacture’s
recommendation (Invitrogen). The recombinant clones were selected on LB agar plates
containing respective antibiotics (kanamycin 50 µg/ml, gentamycin 7 µg/ml and
tetracycline 10 µg/ml). After incubating on the LB agar plates for 24 to 48 hours at 37˚C,
the white clones containing recombinant bacmid DNA were picked up and transferred
into LB medium containing the same antibiotics as LB agar plates. The recombinant
bacmid DNA was purified by using DNA Purification System (Promega) and further
confirmed by PCR analysis (Figure 2).
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The resultant recombinant bacmid DNA was transfected into the seed T. ni cells
(9x105 T. ni cells per 35-mm of a 6-well plate) by using GenePORTERTM transfection
reagent (Gene Therapy Systems). The recombinant virus were harvested at 72 hours after
transfection and further confirmed by PCR analysis (Figure 3).

Baculovirus-mediated CYP2D6 variants expression: T. ni cells were maintained
on 100-mm culture dishes (Sarstedt, Newton NC) at 27˚C using HyQCCM-SFM medium
as described previously. Baculovirus stocks were amplified by subsequent “passages” (up
to two as necessary to achieve suitably high P450 expression) of viral supernatant onto a
new 100-mm dish of T. ni with excess (30ml) medium followed by incubation for 7 to 8
days. Suspension culture were inoculated directly from culture dishes and were grown in
batches of 250 ml in a 2-liter Erlenmeyer flasks using a spin bar on a magnetic stir
platform. Vigorous string was used to reduce cell clumping and to ensure adequate
oxygenation of the medium. Infection was carried out at a cell density of 0.8 to 1.6x106
cells/ml using 1-10 ml of amplified viral supernatant. Freshly prepared heme solution (15 mg/ml dissolved in 10mM NH4OH) was added 2 days postinfection at a 1:1000 dilution
(final heme concentration is 1-5 µg/ml). Cells were pelleted 3 to 4 days postinfection,
resuspended and washed once in glycerol-containing buffer (100mM potassium
phosphate, 20% glycerol, 0.33mM dithiothreitol, 1mM EDTA, PH 7.4), repelleted, and
stored at –80oC until further use.

Microsomes preparation and carbon monoxide difference spectroscopy analysis
of recombinant CYP2D6 variants: 250 ml suspension culture of recombinant T. ni cells
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were harvested at 3000 rpm for 10 minutes, the pellets were washed in once in glycerolcontaining buffer (100 Mm potassium phosphate, 20% glycerol, 0.33 dithiothreitol, 1mM
EDTA, pH 7.4). The pellets were resuspended in homogenization buffer (320mM
sucrose, 10mM KH2PO4, 1mM EDTA, 1mM PMSF, pH 7.4) and further lysated by
French Press. Microsomes of recombinant cells were isolated by series of centrifuges at
9,000 rpm and 40,000 rpm. The microsomal pellets were finally resuspended in freezing
buffer (100mM Kpi, 20% (v/v) glycerol, 1mM EDTA, 1mM PMSF, pH 7.4). In all cases,
carbon monoxide difference spectroscopy analysis was used to determine the enzymatic
activity and concentration of CYP2D6 variants as previously described (39).

Kinetic studies of CYP2D6 allelic isoforms: Incubation reactions were carried out
in 100mM potassium phosphate buffer (pH 7.4) in a final volume of 200 µl., containing
CYP2D6 allelic isoforms, P450 reductase, NADPH and substrate. CYP2D6 and
exogenous reductase were added together incubated at room temperature for 15 min.
Substrate and Kpi buffer were then added and incubated at 37oC for 5 min. Reactions
were initiated by the addition of NADPH and terminated by the addition of 10 µl of 60%
perchloric acid. The mixtures were subjected to centrifugation at 14,000g for 5 min
before HPLC injection and analysis. Dextromethorphan concentrations ranged from 0 to
50 µM for the O-demethylation reaction, the incubations were carried out for 15 min at
37oC. dextromethorphan concentrations ranged from 0 to 10,000µM for N-demethylation
reaction, the incubations were carried out for 15 min at 37oC. Codeine concentrations
ranged from 0 to 3000 µM, and the incubations were carried out for 30 min at 37oC. In
the current study, the reaction time and the amount of enzyme were determined by pre-
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test. Using fixed substrate concentration and the same amount of enzyme but a series of
reaction times carried out the time dependency experiment. The reaction time was
selected within linear part. Using fixed substrate concentration and reaction time but
different amount of enzyme did the enzyme concentration dependency experiment. The
amount of enzyme was selected within the linear part.

Metabolite analyses: HPLC analyses were carried out on a Waters Alliance system
(Milford, MA) consisting of the 2690 separation module, the 2487 dual absorbance
detector, and the 474 scanning fluorescence detector. The Alliance HPLC system was
controlled with Millennium 32 software. A 4.6 x 250 mm, 5mm zorbax phenyl column
(Agilent Technologies) was used to separate the substrates and the metabolites. The flow
rate through the column at room temperature was 1 ml/min. Separation of DXM and its
metabolites were achieved with a mobile phase containing 75% acetonitrile and methanol
mixture (250/200, v/v) and 25% 10mM potassium phosphate buffer adjusted to pH 3.5
with orthophosphoric acid. DXM, DXO (dextrorphan) and MEM (3-methoxymorphinan)
were eluted at 21.992, 10.597 and 17.313 minutes respectively. The excitation and
emission wavelengths, the gain, and the attenuation of the fluorescence detector were set
at 280 and 310 nm, 10, and 32, respectively. A mobile phase consisting of 50% water
(with 0.1% TFA) and 50% acetonitrile and water (400:600, v/v) was used to separate
codeine and its metabolites nor-codeine and morphine, which eluted at 16.891, 12.543
and 7.699 respectively. The excitation and emission wavelengths of the fluorescence
detector were set at 280 and 335nm for the analysis of codeine and its metabolites.

42

Data Analysis and Molecular modeling: Michaelis-Menten Enzyme parameters
(Km and Vmax) were estimated by nonlinear regression (GraphPad Prism v3.02, GraphPad
Software, San Diego, CA). The Homology models of CYP2D6 and its mutants have been
achieved from Swiss-Model (19, 44). The coordinates of the heme cofactor of 1pq2b and
the crystal structure of human cytochrome P450 2C8 were used for the homology models.
Structural alignments of three homology models were performed in Homology Module of
Insight II.

Results

Creation of cDNA of CYP2D6 alleles: 2D6*24 (I297L), 2D6*26 (I369T), 2D6*27
(E410K) and 2D6*33 (A237S). To obtain the cDNA of these alleles, the cDNA of
CYP2D6*1 was used as template to create these mutations by site-directed mutagenesis.
After mutagenesis, the target mutations were confirmed by DNA sequencing analysis
with the primers located at the flank region of these mutagenesis sites. As shown in
Figure 1, these mutations were successfully created in the respective alleles. For example,
ATA (isoleucine) was changed to CTA (lucine) in 2D6*24; ATC (isoleucine) was
changed to ACC (threonine) in 2D6*26; GAG (glutamate) was changed to AAG (lysine)
in 2D6*27; GCT (alanine) was changed to TCT (serine) in 2D6*33. In addition, the fulllength cDNA was sequenced in these alleles and the results indicated the mutations only
occurred in the target sites (data not shown).
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cDNA expression of the CYP2D6 wild type and four allelic isoforms. The creation
of high titer baculovirus stock, the growth of baculovirus, the media conditions, the
infection of T.ni cells with baculovirus and the addition of heme were carried out as
previously described (21, 53). The expression of the CYP2D6 variant cDNA mediated by
baculovirus was confirmed by immuno-blot analysis with monoclonal antibody against
CYP2D6. As shown in Figure 4, the proteins were successfully expressed in the
respective recombinant cell lines but not in the negative control of T. ni cell. In addition,
the molecular weight of these variant proteins is the same as that of the wild type. These
data indicated that the alleles were successfully constructed and expressed in the T. ni cell
lines infected by the recombinant baculovirus.

Enzyme analysis of CYP2D6 alleles. At first, the recombinant baculovirus
containing the cDNA of these alleles were transfected in T. ni insect cells cultured on
serum-fortified plates. The enzymatic activity and yields of CYP2D6 alleles was
measured by carbon monoxide difference spectra. The reduced carbon monoxide
difference spectra of the expressed protein exhibited Soret maxima at 450 nm
characteristic of P450, which indicated that the mutation in these four alleles did not
resulted in the inactivation of CYP2D6 (Figure 5). In addition, the wild type and these
four alleles showed absorbance at 420 nm, indicating the denaturation of some active
enzyme.

In order to obtain sufficient quantities of enzyme for enzymatic analysis, the alleles
were expressed in suspension cultures as previously described (53). Western-blot and
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carbon monoxide difference spectra analysis indicated that these alleles and the wild type
were also successfully expressed in suspension cultures (data not shown). To perform
enzymatic analysis, microsomes were isolated from the suspension culture respectively
expressing these alleles as previously described (32, 50). The activity and concentration
of the enzymes was measure by carbon monoxide difference spectra analysis. The results
indicated that all the enzymes but 2D6.33 behaved in a chromatographically similar
manner throughout the membrane preparation, which means that these enzymes located
in microsomes and are still active after preparation (data not shown). However, 2D6.33
failed to produce absorbance at 450 nm. Instead, it showed strong absorbance at 420 nm,
which implied that the enzyme might be denatured after preparation due to improper pH
and other unknown factors. Thus, only three alleles were prepared for the kinetic studies.

Dextromethorphan O-demethylation by CYP2D6 allelic isoforms. Reconstitution
conditions were described previously (53). Though the addition of lipid is essential for
the metabolic turnover of cytochrome P450s, we did not choose it because we use
membrane preparation. We set exogenous reductase concentration and 2D6 isoforms at a
fixed ration of 2:1 (21). Following incubation (see methods), reaction mixtures were
injected directly onto the column for the HPLC assay to identify the metabolites by
comparison with retention times of authentic standards. Using the HPLC conditions
described, the two metabolites DXO and MEM were eluted at 10.597 minutes and 17.313
minutes respectively, and were verified by fluorescence detection. Kinetic analysis of
DXM O-demethylation activities was carried out with CYP2D6 allelic isoenzymes
(Figure 6). The DXM concentrations range from 0-50 µM. At the low concentration the
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mainly metabolite is DXO, and it follows simple Michaelis-Menten saturation kinetics.
Kinetic parameters estimated from CYP2D6 alleles (Km and Vmax) are given in Table1.
Apparently, for DXM O-demethylation, 2D6.24 have the highest intrinsic clearance
value, as estimated by Vmax/Km ratio, followed by .1, .26 and .27.

Dextromethorphan N-demethylation by CYP2D6 alleles. Following the same
incubation and HPLC conditions, the N-demethylation metabolite 3-MEM was formed
from DXM. At the high concentration (the DXM concentration range from 0 -10,000
µM), the main metabolite of DXM is 3-MEM, 2D6.26 and 2D6.27 appear to follow
simple Michaelis-Menten saturation kinetics (Figure 7c,d). 2D6.1 and 2D6.24 exhibit
atypical profile (Figure 7 a, b) indicating that there is a second-order relationship between
velocity and substrate concentration.

Codeine metabolism by CYP2D6 allelic isoforms. Following the reconstitution
conditions, codeine was also used as a substrate to compare catalytic efficiencies of
CYP2D6 allelic isoforms. Using the HPLC conditions described (see methods), the
metabolites morphine and nor-codeine were clearly separated from substrate codeine.
Morphine, nor-codeine and codeine eluted at 7.699, 12.543 and 16.891 minutes
respectively. Kinetic analyses of codeine metabolism were carried out with the CYP2D6
allelic isoenzymes. For codeine O-demethylation, Michaelis-Menten plots for each allele
are shown in Figure 8. Estimated Km and Vmax values for codeine O-demethylation are
shown in Table 1. CYP2D6.26 and .27 have the same intrinsic clearance, they are around
2 fold higher than wild type CYP2D6 based on Vmax/Km ratio.
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Molecular modeling. As shown in Figure 9, the residue I297 locates at the N
terminal end of I helix, where is close to the active site of CYP2D6. The residue I369 is
in the active site of the enzyme. The residue A237 is in G helix, where affects substrates
entering into the active site. The residue E410 is far away from the active site and seems
to be on the surface. The molecular modeling analysis is consistent with the kinetic
analysis in 2D6.24 and .26 but not in 2D6.27.

Discussion

Although the molecular basis of the CYP2D6 polymorphism has been extensively
investigated, the effects of these mutations in these alleles have not been elucidated in
terms of enzymatic activity and metabolism of substrates. The O-demethylation of DXM
is an established and widely used as an index reaction both in vivo (2, 5, 20, 48)and in
vitro (26, 28) for the metabolic capacity of cytochrome P450 2D6 due to its relative
specificity, safety and over-the-counter availability. Genetic polymorphisms in CYP2D6
result in nonfunctional genotype, thus these patients lack CYP2D6 enzyme (~7% of
Caucasians). Codeine can be converted to morphine by CYP2D6. However, the CYP2D6
poor metabolizers obtain minimal/no analgesia from codeine, so CYP2D6 PMs seem
protected from oral opiate dependence. Studying pharmacogenetics of codeine and
CYP2D6 shed light on clinical recommendations, patients with chronic pain to be treated
with narcotic analgesics should be CYP2D6 genotyped to identify the PMs, and thus
avoid giving them analgesics that will be completely ineffective.
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In the current study, we selected four CYP2D6 alleles to test if these allelic isoforms
on enzyme activity are substrate dependent. Dextromethorphan is metabolized to 3methoxymorphinan through N-demethylation as well as dextrorphan through Odemethylation by CYP2D6.1. These two metabolites were tested in reactions catalyzed
by 2D6.24, .26, and .27. For 2D6.1 and three allelic isoforms, MEM/DXO increased with
DXM concentration increasing (Figure 10). This is consistent with previous study
reported that the DXM N-demethylation product continues to be formed at higher
substrate concentration far beyond the point of saturation for the O-demethylation
reaction (Figure 6). This result indicated the possibility that these reactions are achieved
through an alternate binding orientation or active site.

DXM can be converted to DXO through O-demethylation and MEM through Ndemethylation. In 2D6.24, isoleucine is replaced by leucine. Because MEM/DXO ratio
increased with DXM concentration increasing, and MEM/DXO ratio produced by 2D6.24
is higher than MEM/DXO ratio produced by 2D6.1 (Figure 10), it can be predicted that
residue isoleucine may play a role in dictating substrate orientation within the active site
of CYP2D6. In 2D6.26, isoleucine is replaced by threonine, the hydrophobic amino acid
(Ile) is changed to hydrophilic amino acid (Thr). In 2D6.27, glutamic acid is replaced by
lysine, the negative charged rsidue (Glu) is changed to positive charged residue (Lys).
According to amino acid structures, we can predict that CYP2D6.26 and .27 may have
effect on enzyme activity. Based on our experimental results, CYP2D6.24 has higher
enzyme efficiency for DXM O-demethylation compared to 2D6.1. 2D6.26 and .27 have
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the same intrinsic clearance for codeine O-demethylation, they are 2-fold higher than
2D6.1 based on V/K ration.
In this study, membrane preparation wild type CYP2D6 formed DXO as the major
metabolite with a Km of 0.60 ± 0.16 µM and a Vmax of 0.73± 0.04 pmol/pmol/min
(Table1). Ching (3) measured a Km of 5.4 µM and Vmax of 0.47 nmol/nmol/min by using
the extract of a yeast expression system containing CYP2D6*1 cDNA, which is similar to
the Km value of 8.5 µM and Vmax of 0.7 nmol/nmol/min reported by Krynetski et al.
(31). Yu et al. also indicated a Km of 6.2 µM and Vmax of 14 nmol/nmol/min with
purified 2D6 and there was a steady decline in the apparent Km and leveling off of Vmax
using a relatively short assay time (53). Overall, there are many factors that might affect
the values for the kinetics of dextromethorphan O-demethylation, e.g. different
expression systems, different assay time and whether it is purified enzyme or membrane
preparation.

In the current work, we found that these three allelic isoforms produce more
morphine than nor-codeine compared to the wild type CYP2D6, which produces more
nor-codeine than morphine, I369T exhibited higher enzyme efficiency for codeine Odemethylation than codeine N-demethylation compared to the wild type CYP2D6 and
other alleles. However, according to the Michaelis-Menten curves, the formation of norcodeine reaches to saturation quickly, it does not show very good Michaelis-Menten
kinetics (data not shown). One reason may be due to the higher substrate concentration
since it is critical that kinetic studies should be performed at physiologically relevant
substrate concentrations in order to relate in vitro findings to the clinical setting.
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Theoretically, about 10% of a dose of codeine is converted to morphine in the body by
CYP2D6, a dose of approximately 200 mg (oral) of codeine must be administered to give
equivalent analgesia to 30 mg (oral) of morphine (22). It is not used, however, in single
doses of greater than 60 mg (and no more than 240 mg in 24 hours) since there is a
ceiling effect. In this study, the concentration of codeine ranges from 0-3000 µM, and we
use membrane preparations that are not the purified enzyme and they may need higher
substrate concentration to get good Mechaelis-Menten curves.

Gotoh provided six separate regions that were tentatively assigned as substrate
recognition sites (SRSs) in CYP2D proteins according to the sequence alignment
between representative CYP2D members and P450 101A. These sites include B’ and
flanking areas (103-126), the C-terminal end of Helix F (209-216), the N-terminal end of
Helix G (248-255), the N-terminal half of Helix I (302-320), the 3 area (378-385) and a
central region of 5 (485-493) (14). None of the mutations in these alleles locates at those
regions, which suggested that these nucleotide substitutions probably do not influence the
binding of specific substrates. This speculation is not consistent with our experimental
results since these allelic isoforms except for CYP2D6.27 showed difference with the
wild type CYP2D6 in terms of the intrinsic clearance of these two substrates.
CYP2D6.24 is around 5 fold higher than CYP2D6.1 in terms of the metabolism of
dextromethorphan (Table1). According to the structural model of CYP2D6, the mutation
in CYP2D6.24 is located at the end of I helix (Figure 9), which may affect I helix and
further influence the binding specificity of dextromethorphan. However, it has no effect
on codeine binding. The 2D6.26 shows 2-fold increase in the O-demethylation of codeine
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but not for DXM (Table 1). Based on molecular modeling analysis, 2D6.26 is located in
the active site, which may influence codeine binding but not on dextromorphan
metabolism. These results imply that the effect of these allelic variations on enzyme
activity is substrate dependent. 2D6.27 has the same enzyme efficiency as 2D6.26 for
codeine O-demethylation. This result is not consistent with molecular modeling analysis
because the substitute residue E410 in 2D6.27 is far away from active site. Molecular
docking study may be necessary for further study. For 2D6.33, mutation from AS will
change the hydrophobic propensity and further affect the stability of the secondary and
tertiary structure, this might be one of the reasons that this enzyme is not stable during
membrane preparation process.

In summary, there are several strategies and methods for CYP2D6 genotyping, such
as PCR-SSCP, real-time PCR, microarrays for DNA analysis, TaqMan real-time PCR,
and XL-PCR and PCR-RFLP. CYP2D6 genotyping is a useful tool in clinical medicine.
At the meantime, the analysis of the various new mutations and alleles should lead to
more information regarding their consequences on catalytic activity and substrate
specificity of the CYP2D6 enzyme. In current study, CYP2D6.24 exhibited higher
enzyme efficiency (estimated as Vmax/Km) for dextromethorphan O-demethylation
compared to the wild type CYP2D6 and the other allelic isoforms. 2D6.26 and 2D6.27
showed higher enzyme efficiency for codeine O-demethylation compared to 2D6.1.
Molecular modeling results indicated that residues I297 and I369 were located in the
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active site of 2D6 homology model, mutations (I297L) and (I369T) of these residues may
affect substrate binding and further affect drug metabolism.

Figure legends
Figure 1
Creation of four alleles confirmed by DNA sequencing analysis. Four alleles were
constructed based on CYP2D6*1 cDNA by site-directed mutagenesis. Four primers were
used for sequence, 2D6 5’, C82, C534 and C1011. A changed to C in CYP2D6*24
(I297L); T changed to C in CYP2D6*26 (I369T); G changed to A in CYP2D6*27
(E410k) and G changed to T in CYP2D*33 (A237S).

Figure 2
Generation of recombinant bacmid DNA. Four constructed alleles (in pFastBac I) were
transformed into DH10Bac competent cells, these cells contain bacmid DNA.
Recombinant bacmid DNA can be obtained after homogeneous recombination.

Figure 3
Confirmation of recombinant bacmid DNA by PCR. The recombinant bacmid DNAs
were confirmed by PCR. For PCR reaction, the forward primer is 2D6 5’that can bind to
2D6 gene, the reverse primer is M13 reverse that can bind to bacmid DNA. The PCR
condition is: 94˚C 4 minute for 1 cycle followed by 94˚C 45 seconds, 55˚C 45 seconds
and 72˚C 5 minutes for total 35 cycles. The size of PCR product is 2074bps.
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Figure 4
Analysis of four allelic variations by western blot. The four constructed alleles were
over-expressed in T.ni insect cells using baculovirus expression system. The expressed
protein were separated by SDS-PAGE, proteins were transferred into PVDF membrane.
CYP2D6 monoclonal antibody was used for western blot.

Figure 5
Carbon monoxide difference spectroscopy of CYP2D6 allelic isoforms. Spectra were
determined by the method of Omura and Sato (1964).

Figure 6
Dextromethorphan O-demethylation by CYP2D6 allelic isoforms. Mmebrane
preparations of wild type CYP2D6 and the three allelic variants were isolated from insect
cells. The enzymes were individually reconstituted in an environment with cytochrome
P450 reductase and different concentrations of dextromethorphan (DXM). DXM
concentration ranges from 0 to 50 µM. Reactions were initiated by the addition of
NADPH and terminated by the addition of 60% perchloric acid. Michaelis-menten curves
showed the rates of DXO formation from DXM catalyzed by the wild type CYP2D6.1
and CYP2D6.24, .26 and .27. •, CYP2D6.1 (WT); , CYP2D6.24 (I297L); ,
CYP2D6.26 (I369T); , CYP2D6.27 (E410K).
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Figure 7
Dextromethorphan N-demethylation by CYP2D6 allelic isoforms. The enzymes of
CYP2D6.1 and three allelic isoforms were individually reconstituted in an environment
with cytochrome P450 reductase and DXM. DXM concentration ranges from 0 to 10,000
µM. the reactions were initiated by the addition of NADPH and terminated by the
addition of 60% perchloric acid. Michaelis-menten curves showed the rates of MEM
formation from DXM by CYP2D6.26 (Figure 7c) and CYP2D6.27 (Figure 7d).
CYP2D6.1 (Figure 7a) and CYP2D6.24 (Figure 7b) exhibited atypical kinetic profiles.

Figure 8
Codeine O-demethylation by CYP2D6 allelic isoforms. The enzymes of CYP2D6.1
and three allelic isoforms were individually reconstituted in an environment with
cytochrome P450 reductase and codeine. Codeine concentration ranges from 0 to 3,000
µM. the reactions were initiated by the addition of NADPH and terminated by the
addition of 60% perchloric acid. Michaelis-menten curves showed the rates of morphine
formation from codeine catalyzed by the wild type CYP2D6.1 and CYP2D6.24, .26, and
.27. •, CYP2D6.1 (WT); , CYP2D6.24 (I297L); , CYP2D6.26 (I369T); ,
CYP2D6.27 (E410K).

Figure 9
CYP2D6 homology model with four mutation sites marked. The Homology models of
CYP2D6 and its allelic variations have been achieved from Swiss-Mode. The coordinates
of the heme cofactor of 1pq2b and the crystal structure of human cytochrome P450 2C8
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were used for the homology models. Structural alignments of four homology models
were performed in Homology Module of Insight II. I297L (CYP2D6.24) and I369T
(CYP2D6.26) are located in the active site of 2D6.1 homology model, 2D6.24 is located
in I helix. A237S (CYP2D6.33) is located in G helix. E410K (CYP2D6.27) is located on
the surface. Heme is indicated in red.
Figure 10
Ratio of MEM and DXO produced by CYP2D6.1 and three allelic isoforms. DXM
concentration ranges from 0 to 10,000 µM for dextromethorrphan N-demethylation.
Three concentrations (1000, 1700, and 2500µM) were selected to determine the ratio of
MEM (N-demethylation product) and DXO (O-demethylation product) catalyzed by
CYP2D6.1 and three allelic isoforms. Different color represents different substrate
concentration.
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Table 1. Kinetic parameters for DXM O-demethylation and codeine O-demethylation
Reaction

Dextromethorphan O-demethylation

Codeine O-demethylation

Allelic variants

Km

Vmax

V/K

CYP2D6*1

0.60 ± 0.16

0.73 ± 0.04

1.22

CYP2D6*24

0.69 ± 0.06

4.76 ± 0.08

6.90

CYP2D6*26

3.93 ± 0.22

2.98 ± 0.05

0.76

CYP2D6*27

1.45 ± 0.3

0.63 ± 0.03

0.43

CYP2D6*1

13.01 ± 4.04

0.79 ± 0.03

0.06

CYP2D6*24 37.33 ± 7.15

1.24 ± 0.05

0.03

CYP2D6*26 26.73 ± 10.45 2.37 ± 0.19

0.09

CYP2D6*27 10.89 ± 2.12

0.09
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Abstract

Both basic and clinical studies have shown that MPTP (methyl-phenythetra
hydropyridine, an inducer of Parkinson’s disease) and dopamine are related to
Parkinson’s disease. Recent studies have shown that CYP2D6 is not only involved in the
metabolism of MPTP and biosynthesis of dopamine, but also presents in human brain
tissues. These data imply that CYP2D is probably related to Parkinson’s disease.
However, no functional CYP2D had been identified from human brain tissues until Pai et
al recently cloned a very unique CYP2D7 variant in human brain, encoding a functional
protein as result of repair and alternative splicing of mRNA from the CYP2D locus.
However, the structure and functions of this enzyme are poorly understood compared to
those of CYP2D6. In this study, this CYP2D7 variant was successfully crated based on
CYP2D6 by using different genetic tools, and further was expressed in a baculovirus
expression system. Although the immun-blot analysis showed that the full-length
CYP2D7 was successfully expressed, the expressed protein does not have enzymatic
activity of P450 based on CO-reduce activity when the heme was used as an iron source.
Interestingly, the expressed protein restored the activity when -ALA, a precursor of
heme, was used as an iron source. In addition, our preliminary study indicated that the
protein of CYP2D7 variant is predominantly present in the mitochondrial fraction instead
of endoplasmic reticulum. Along this line, the metabolism studies show that the
mitochondrial fraction of the insect cell expressing CYP2D7 variant is capable of
metabolizing codeine and probably m-tyramine but not MPTP. In summary, the obtained
results could not confirm Pai’s study. This study will lead us to further understand the
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catalytic characteristics of this enzyme and its functions in terms of the metabolism of
drugs in human brain tissues and development of CNS diseases.

Introduction

Cytochrome P450s are a superfamily of heme containing enzymes that catalyze the
oxidation of a wide range of xenobiotics chemicals including drugs, carcinogens, and
steroids (13, 15, 38). CYP2D subfamily includes CYP2D6, CYP2D7 and CYP2D8P at the
CYP2D locus. These three genes share 92-97% similarities with each other (22). The
CYP2D8P is a pseudogene since there is frame shift mutation and stop codon within its
exons while CYP2D7 was found to have an insertion in its first exon that disrupts the
reading frame of the protein. Cytochrome P4502D6 (CYP2D6) is one of the most
important phase I drug metabolizing enzymes, it is involved in the oxidation of over 40
commonly prescribed drugs including antiarrhythmics, antihypertensives, ß-blockers,
opioids, antipsychotics and tricyclic antidepressants (14, 20, 30). CYP2D6 is associated
with polymorphic debrisoquine metabolism.

CYP2D6 is predominantly expressed in human liver and mediates metabolism of a
variety of drugs. However, there is increasing evidence that CYP2D6 is also expressed in
extrahepatic tissues and may contribute to the local in situ metabolism of drugs and
activation of carcinogens and toxins (24). CYP2D6 mRNA was detected in all assayed
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regions of human brain, with highest levels observed in cerebellum and lowest levels in
putaman, globus pallidus and substantia nigra (28). In addition, immunoblot studies
demonstrated the presence of CYP2D protein in cortex, cerebellum, midbrain, striatum
and thalamus of human brain (4). Along these lines, clinical studies showed that defects
in the CYP2D6 have been associated with a number of CNS diseases such as Parkinson’s
disease (39), Alzheimer’s disease (42), neuroleptic-induced disorders such as tardive
dyskinesia (33) and certain types of CNS cancer (8, 45).

The primary deficit in Parkinson’s disease is a loss of the neurons in the substantia
nigra pars compacta that provide dopaminergic innervation to the striatum (caudate and
putamen). This paralleled the loss of neurons from the substantia nigra, suggesting that
replacement of dopamine could restore function (7, 19). These fundamental observations
led to an extensive investigative effort to understand the metabolism and actions of
dopamine and to learn how a deficit in dopamine gives rise to the clinical features of
Parkinson’s disease. Studies indicated that L-tyrosine can be converted to tyramine by
aromatic L-amino acid decarboxylase, and tyramine further catalyzed to dopamine by
CYP2D6. Among the 11 isoforms of human CYP expressed in yeast, CYP2D6 is the only
isoform exhibiting strong ability to convert tyramine to dopamine (17). In addition,
CYP2D6 can metabolize MPTP that is a potent inducer of Parkinson’s disease.
However, the link between CYP2D6 and Parkinson’s disease is a controversy.
Phenotypic studies have failed to support the relationship between CYP2D6 and
Parkinson’s disease, the genetic studies initially indicated a link between CYP2D6B
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mutations and Parkinson’s disease, but critical analysis of the literature and studies
emerging from independent laboratories fail to confirm speculation (39).

The liver is the major organ involved in CYP2D6-mediated metabolism. However,
the regional and cellular expression of CYP2D6 in human brain has been identified (28),
which implies that human brain may be another target tissue for drug metabolism. We are
very interested in finding the fact whether there is a unique CYP2D enzyme found only
in human brain that is different from the well-characterized form found in the liver.
Recently, Pai found a CYP2D7 variant in human brain, but it is not present in human
liver or kidney. The brain variant CYP2D7 has a partial inclusion of intron 6 (57bps) in
the transcribed mRNA sequence and contains the 138delT mutation. It has been
confirmed that this enzyme can be expressed as a functional protein as result of repair in
human and it can metabolize codeine to morphine with greater efficiency compared to the
corresponding activity in cells expressing CYP2D6 (36). However, the catalytic
characteristics, substrates of this enzyme and its functions in human brain are poorly
understood.

In this study, we hypothesized that this human brain unique CYP2D7 variant has
specific catalytic ability to metabolize codeine, m-tyramine and other substrates. To test
this hypothesis, the cDNA of this variant was successfully constructed by using sitedirected mutagenesis method based on CYP2D6*1 cDNA, and further expressed in
baculovirus-mediated expression system. Several potential substrates for this enzyme
were analyzed by metabolite study.
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Materials and methods

Bacterial strains, cell line and culture conditions: Escherichia coli strain BMH
71-18 mutS was used for plasmid amplification (Clontech). E. coli XL1-Blue
supercompetent cell (Stratagene) was used to perform site-directed mutagenesis; E. coli
DH10BAC strain (Invitrogen) was used to construct and select recombinant bacmid DNA.
The E. coli strains BMH 71-18 mutS and DH10BAC were cultured in Luria Bertani
medium and XL1-Blue strain was cultured in NZY+ broth at 37˚C. T. ni insect cell line
was used for infection of baculovirus and expression of recombinant proteins
(Invitrogen). The cell line was cultured in HYQ®SFX-INSECT medium (HyClone)
containing 10% fetal bovine serum at 27˚C. Penicillin-G (100 µg/ml), streptomycin
sulfate (61µg/ml) and amphoterecin-B (0.6 µg/ml) were routinely added to the medium to
reduce contamination by bacteria or fungi.

Chemicals: Dextromethorphan, dextrorphan, 3-methoxymorphinan and cumene
hydroperoxide were purchased from Sigma/RBI (Natick, MA). Codeine, nor-codeine,
morphine, trifluoroacetic acid (TFA), and 60% perchloric acid were purchased from
Sigma-Aldrich (St.Louis, MO). Methanol and orthophosphoric acid were purchased from
Fischer Scientific. Gene PORTER Transfection Reagent was purchased from Gene
Therapy System, Inc.
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Primers design and Site-directed mutagenesis: CYP2D6*1 cDNA was used as a
template to create the cDNA of human brain CYP2D7 variant by site-directed
mutagenesis. The mutation sites and primers for mutations were listed in Table 1.
QuikChange® multi site-directed mutagenesis kit was used to create site mutation
(Stratagene). The experiments were carried out as the manufacture’s recommendation.
Briefly, the mutagenesis reactions includes 10 x QuikChange® multi reaction buffer 2.5
µl, QuikSolution 0.75 µl, ds-DNA template (CYP2D6*1) 3 µl, mutagenic primers 2 µl,
dNTP mix 1 µl, QuikChange® multi enzyme blend 1 µl, double distilled H2O to a final
volume of 25 µl. The PCR cycling parameters includes 95 °C 1 minute, 1 cycle for the
first segment; 95 °C 1 minute, 55 °C 1 minute, 65 °C 12 minutes, 30 cycles for the
second segment. The resultant PCR products were treated with 1 µl of Dpn I restriction
enzyme (10U/ µl) to create mutated single strand DNA, which was further transformed
into XL100-Gold Ultracompetent cells. Transformed cells were first plated on agar
plates containing ampicillin (100 µg/ml) and incubated at 37 °C overnight, and then
single clones were picked up and transferred into LB broth and grew at 37 °C overnight
in incubator (250 rpm/minute). Plasmids were isolated with Wizard Plus SV
Minipreprs Kit (Promega). All the target mutations were confirmed by DNA sequencing
analysis. The resultant construct was named as pFB2D6m.

Cloning and insertion of 57 base pairs fragment: The alignment analysis
indicated that there is an extra 57bp fragment present in the cDNA of CYP2D7 variant,
and this fragment encodes 19 amino acids (Figure 1). In order to obtain the full-length
CYP2D7 cDNA, the following strategy was used. First, two restriction endonuclease cut
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sites Aat II and Nru I were created on the mutated CYP2D6 (pFB2D6m) by site-directed
mutagenesis with a primer (5’-CACTTGGA CGTCCAGCGCCGTCGCGAACAGGAG3’), which will be used as a insertion site of the 57bp fragment. Second, a 57bp DNA
fragment was artificially synthesized in Invitrogen, and the resultant product was used as
a template to amplify this fragment by PCR with a pair of primers that have the same cut
sites. The resultant PCR product was purified, and further cloned into PCR cloning vector
pGEM-T easy vector. The inserted 57 bps fragment was digested with Aat II/Nru I, and
re-ligated to the same sites on the pFB2D6m, and resulted in the construct pFB2D7m.
The mutation sites for Aat II/Nru I located on pFB2D7m were removed by reverse
mutation mediated by site-directed mutagenesis with two primers: (5’-CACTTGGAT
GTGCAGCGAGGAAGG-3’and 5’-CCAGTCCGTGTCCAACAGGAGATC-3’), and
created the final construct pFB2D7v.

DNA sequencing analysis: All the target mutations and insertion for creating the
cDNA of CYP2D7 variant were confirmed by DNA sequencing analysis (Northwoods
DNA, Inc) with four different primers: 2D6-5’ (5’-GGATTATTCATACCGTCC-3’),
C82 (5’-CGCTGGGCT GCACGC-3’), C534 (5’-GGACAAAGCCGTGAG-3’), and
C1011 (5’-CGTGATAGGGCA GG-3’).

Construction of recombinant baculovirus: The construct pFB2D7v was
transformed into DH10Bac competent cells (Invitrogen), which contain the bacmid with
mini-attTn 7target site and the help plasmid. After incubating on the Luria agar plates for
24 to 48 hours at 37 °C, white clones which contain recombinant bacmid DNA were
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picked up and transferred into LB medium with 50 µg/ml kanamycin, 7 µg/ml
gentamicin, and 10 µg/ml tetracycline, grew at 37 °C (up to 24 hours), shaking at 250
rpm. The recombinant bacmid DNA was purified and characterized by PCR. The
recombinant bacmid DNA was further treated with GenePORTER TM transfection
reagent (Gene Therapy System), and transfected into seed 9x105 T.ni cells per 35-mm (of
a 6-well plate) at 27 °C in 2 ml of SFX-INSECT (Hyclone) containing 10% fetal bovine
serum and 100 µg/ml Penicillin-G, 60 µg/ml Streptomycin sulfate, 0.6 µg/ml
Amphoterecin-B. The recombinant virus was harvested at 72 hours after transfection.
Baculovirus stocks were amplified by subsequent passages onto a new 100-mm dish of
T.ni cells with 30 ml medium followed by incubation for 7 to 8 days.

Protein expression and subcellular fraction purification: Seed (2 x 106) T.ni cells
per 100-mm at 27º C in 10ml of medium. Suspension culture were inoculated directly
from culture dishes and were grown in batches of 250 ml in a 2-liter Erlenmeyer flasks
using a spin bar on a magnetic stir platform. Vigorous stirring was used to reduce cell
clumping and to ensure adequate oxygenation of the medium. Infection was carried out at
a cell density of 1.6 to 2.0 x106 cells/ml using 8-12 ml of amplified viral supernatant. ALA (finial concentration 500 µm) was added together with virus. Cells were harvested 3
to 4 days post-infection, re-suspended and washed once in storage buffer (100mM
potassium phosphate, 20% glycerol, 0.33mM dithiothreitol, 1mM EDTA, PH 7.4),
repelled and stored at -80 °C for further use.
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250 ml culture was harvested, and the cell pellet was re-suspended in 10 ml
homogenization buffer (320mM sucrose, 10mM KH2PO4, 1mM EDTA, 1mM PMSF, pH
7.4). The resultant sample was then treated with French Cell Press to break cells followed
by centrifuge at 600 g for 5 minutes to remove insoluble cell debris. The supernatant part
was centrifuged at 3000 g for 20 minutes to collect mitochondria. The pellet containing
mitochondria was re-suspended in solubilization buffer (100mM Kpi, pH 7.4, 20%
glycerol, 1mM EDTA, 0.1mM DTT, 0.2mM PMSF, 1% cholate). The supernatant was
then re-centrifuged at 40,000rpm for 1 hour, and the pellet, which contains rough ER,
smooth ER and microsomes, was re-suspended in freezing buffer (100mM Kpi, 20%(v/v)
glycerol, 1mM EDTA, 1mM PMSF, pH 7.4).

SDS-PAGE and Western-blot analysis: SDS-PAGE and Western-blotting with the
enhanced chemiluminescence detection method were carried out as reported. Polyclonal
and monoclonal antibodies against human CYP2D6 were purchased from BD GentestTM
and PANVERA. Briefly, the same amounts of samples were loaded in 10% SDS-PAGE.
After electrophoresis, the samples were transferred to immuno-blot PDVF membrane.
The resultant blots were blocked in 5% fat free milk at room temperature for 1 hour, and
then incubated in 2% milk containing primary antibodies for 1 hour at room temperature
followed by three times wash by using TPBS. The blots were developed by using
horseradish peroxidase-conjugated secondary antibody with the ECL luminal assay.

Metabolite analysis of CYP2D7 variant: Kinetic studies of CYP2D7 were carried
out as previous studies. Briefly, reactions were performed in 100mM potassium
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phosphate buffer, pH 7.4, containing mitochondria fraction (0.27 µM), cumene
hydroperoxide (CuOOH, 500 µM), and substrates in a final volume of 200 µl. CYP2D7
variant, the substrates and potassium phosphate buffer were first added together, then
incubate at 37°C for 5 minutes. Reactions were initiated by addition of CuOOH, and
terminated by addition of 10 µl 60% perchloric acid. The mixtures were subjected to
centrifugation at 14,000rpm for 10 minutes before HPLC injection and analysis. When
codeine was used as substrate, the substrate concentration was 2000 µM, the incubation
was carried out at 37°C for 30 minutes. When m-tyramine was used as substrate, the
substrate concentration was 500 µM, the reaction was incubated for 20 minutes at 37°C.
When MPTP was used as substrate, the concentration of substrate was 250 µM.

HPLC analysis was carried out on a Waters Alliance System (Milford, MA)
consisting of the 2690 separation module, the 2487 dual wavelength absorbance detector
and the 474 scanning fluorescence detector. The data was analyzed with Millennium 32
software. A 250 x 4.6 mm i.d. phenyl column was used to separate codeine and its
metabolite. A 150 x 4.6mm Phenomenex deactivated column was used to separate mtyramine and its metabolite; MPTP and its metabolite PTP. The flow rate through the
column at room temperature was 1 ml/minute. Separations of codeine and its metabolites
were achieved with a mobile phase containing 50% water (with 0.1% TFA) and 50%
acetonitrile with water (400:600, v/v). The excitation and emission wavelength of the
fluorescence detector were set at 280 and 335 nm. A mobile phase consisting of 98% 10
mM KH2PO4 (pH 3.5) and 2% acetonitrile and methanol (250:200, v/v) was used to
separate m-tyramine and dopamine. The excitation and emission wavelength of the
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fluorescence detector was set at 280 and 380 nm. A mobile phase consisting of 40%
acetonitrile and 60% 25mM potassium phosphate (PH7.4) was used to separate MPTP
and PTP. The excitation and emission wavelength of fluorescence detector was set at 244
and 307nm.

Mass spectrometry: ESI-MS was used to identify the metabolites as previously
described. Briefly, nitrogen was used as sheath gas (100psi) at a flow rate of 20 arbitrary
units. An electrospray voltage of 4.5 kV and a capillary temperature of 200 °C were used.
The infusion rate was 10 µl/min. The maximum ion injection time was set to 800 ms. The
ion isolation window was set at 1 Th and collision energies were set at 20 –35%. Ultrahigh purity helium was used as the buffer gas. For m-tyramine metabolism, the reaction
mixture was diluted in 50% methanol and 50% acetonitrile to the final concentration of 1
µg/ml just before analysis.

Results

Construction the cDNA of human brain CYP2D7 variant. The cDNA of CYP2D6
and the CYP2D7 variant shares about 97% identity. Sequence alignment analysis
indicated that there are 30 different genetic codes that cause alternation of amino acids
(Figure 1). In order to obtain the cDNA of CYP2D7 variant, these sites were alternated by
site-directed mutagenesis based on the cDNA of CYP2D6*1. The sites of mutation and
the primers for mutagenesis were listed in Table 1. After many cycles of mutations, all
these sites were successfully altered and identical to those of CYP2D7 variant. In
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addition, CYP2D7 variant contains an extra 57 bps DNA fragment, which encodes 19
amino acids. In order to obtain the full-length cDNA of CYP2D7 variant, the strategy
described in the method was used to insert this fragment into the target site at the mutated
CYP2D6. The final construct was confirmed by DNA sequencing analysis, and the results
indicated that the amino acid sequence encoded by the constructed CYP2D7 variant are
100% identical to that described by Pai (36).
Construction of recombinant bacmid DNA. To create recombinant baculovirus,
the constructed 2D7 variant cDNA was transformed into DH10Bac competent cells
containing the bacmid, constructed 2D7 variant cDNA can combine with bacmid DNA
by homogeneous recombination. The recombinant bacmid DNA was confirmed by PCR
(Figure 2a). If CYP2D6 is integrated into baculovirus DNA, The size of PCR product is
expected to be 2,074bps. 2D7 variant is 57-bp bigger than 2D6, it is expected to be
2,131bps. The result indicated that the constructed 2D7 variant cDNA was successfully
integrated into baculovirus DNA.

Expression of CYP2D7 variant. Several P450 enzymes including CYP2D6 and
CYP2C9 were successfully expressed in the insect cell lines mediated by baculoviurs. In
order to obtain the active CYP2D7 variant enzyme, the same expression system was
used. The creation of high titer baculovirus stock, the growth of baculovirus, the media
conditions, the infection of T. ni cells with baculovirus were described previously (16,
46). To detect whether the CYP2D7 variant was expressed in the transfected insect cells,
Western-blot analysis was carried out with the polyclonal and monoclonal antibodies
against to CYP2D6, and results showed that CYP2D7 variant reacted to both antibodies
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(Figure 2b). As shown in Figure 2b, the molecular weight of CYP2D6 is about 50kD; and
the molecular weight of CYP2D7 variant is about 57kD, which is the same as the
predicted molecular weight based on the sequence of amino acids. These data showed
that the protein of CYP2D7 variant was successfully expressed in baculovirus-mediated
expression system.

Enzymatic analysis and localization of human brain CYP2D7 variant. In order
to determine the enzymatic activity of expressed CYP2D7 variant, the carbon monoxide
difference spectra was performed as previously described. However, no activity was
detected when Heme was used as a resource of Fe3+. The same pattern was observed with
different experimental conditions such as different cell culture, different amount and
preparation and addition time of Heme (data not shown). -aminolevulinic acid (-ALA)
is the other commonly used resource providing Fe3+ for P450 (37). When -ALA was
used, carbon monoxide difference spectra analysis of the expressed protein exhibited
Soret maxima at 450nm characteristic of P450. It also showed a strong absorption at
420nm, indicating there is denature of some active enzyme (Figure 3).
Different cell fractions were prepared from T. ni insect cells transfected with CYP2D7
variant. Mitochondria and microsomes were isolated separately. Interestingly, no
enzymatic activity was detected in the microsome fraction by carbon monoxide
difference spectra analysis. Instead, the enzymatic activity was present in the
mitochondrial fractions, which implied that CYP2D7 variant might locate at the
mitochondria of insect cells. To detect this hypothesis, Western-blot analysis was
performed to detect the location of CYP2D7 variant. As shown in Figure 4, the CYP2D7
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variant was predominantly present in the mitochondrial fraction instead of microsome
fraction. In contrast, CYP2D6 is predominantly present in microsome fraction. These
results implied that human brain CYP2D7 variant might have different cellular location
compared to human liver CYP2D6.

Metabolism of codeine, tyramine and MPTP by human brain CYP2D7 variant.
This unique variant was identified in human brain, and it has not been found in other
organs. It implies that this variant may have tissue specificity, and might have unique
catalytic activity in terms of the metabolism of neuro-drugs, transmitter and toxins. To
test this hypothesis, the following substrates were chosen for the metabolism analysis:
Codeine, a commonly used neuro-drug; m-tyramine, precursor of dopamine that is related
to Parkinson’s disease; MPTP, an inducer of dopaminergic neurotoxicity. As mentioned
above, the CYP2D7 variant was predominantly present in the mitochondrial fraction from
the transfected insect cells. Thus, this mitochondrial fraction was used for the following
metabolism studies.

a. Codeine O-demethylation by CYP2D7 variant. Reconstitution conditions
were described previously (see methods). Following incubation, reaction mixtures were
injected directly onto the column for the HPLC assay to identify the metabolites by
comparison with retention times of authentic standards. Using the HPLC conditions
described, the metabolites morphine and nor-codeine were clearly separated from
substrate codeine. Morphine, nor-codeine and codeine eluted at 7.699, 12.543 and
16.891min, respectively (Figure 5a), they were verified by fluorescence detection.
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Kinetic analysis of codeine O-demethylation activities was carried out with CYP2D7
variant and CYP2D6*1. As shown in Figure 5b, both CYP2D6*1 and CYP2D7 could
metabolize codeine to morphine. However, the velocity value for the metabolism of
codeine by CYP2D7 was 1.23 pmol/min, which is faster than that of CYP2D6*1
(velocity value 0.53 pmol/min) (Table 2). These results implied that human brain
CYP2D7 variant might have a unique capability to metabolize the drugs predominantly
present in human brain.

b. M-tyramine metabolism by CYP2D7 variant. The standard m-tyramine and
dopamine mixture was injected directly onto the column for the HPLC assay to identify
the retention times of the standards. Using the HPLC conditions described in the method,
m-tyramine and dopamine were clearly separated, with retention times of 3.913 and
7.901 min, respectively (Figure 6a). The same products were also detected in the reaction
mediated by CYP2D7 variant, which indicated that CYP2D7 variant could also convert
m-tyramine to dopamine (Figure 6b). The velocity value for the metabolism of tyramine
to dopamine was 2.0 pmol/min (Table2). However, the same product (retention time,
3.913 min, 7.901 min) was also found in the negative control that is mitochondrial
fraction isolated from T. ni cells (Figure 6c). Because constructed 2D7 variant is mostly
located in mitochondria fraction of insect cells, mitochondria fractions were used for
kinetic studies. Both mitochondria fractions, from insect cells and from insect cells
expressing 2D7 variant were isolated from the same amount of T.ni insect cells in
suspension culture. As described in method, two mitochondria fractions were resuspended in the same amount of solubilization buffer, and the same volume was used for
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kinetic studies. ESI-MS analysis indicates that the m/z ratio of the metabolite that is
produced by mitochondria fraction from insect cells expressing 2D7 variant is about
149.3 (Figure 7c), which is the same as the m/z of standard dopamine (Figure 7a), and the
m/z ratio of the product produced by mitochondria fraction from insect cells is also the
same as the m/z of standard dopamine (Figure 7b). These data indicated that some
proteins or enzymes present in T. ni cells could also convert m-tyramine to dopamine.

c. MPTP metabolism by CYP2D7. The activity of constructed CYP2D7 variant
was determined by examining the metabolism of MPTP to PTP. The standard MPTP and
PTP mixture were injected directly onto the column for the HPLC assay to identify the
retention times of the standards. Using the HPLC conditions described, MPTP and PTP
were clearly separated, with retention times of 8.842 min and 4.026 min, respectively.
However, no product was detected at retention time 4.026 min in the reaction catalyzed
by CYP2D7 variant, which indicated that it could not metabolize MPTP to PTP (data not
shown).

Discussion

Siegle provided evidence that CYP2D6 is expressed in certain regions of the human
central nervous system (CNS) (41). This report shed light on the genetic polymorphism
of this enzyme that might be responsible for a number of drug interactions not only in the
liver, but also in the human brain. Pai reported the presence of a unique variant of P450
named CYP2D7 in the human brain and not in human live or kidney (36). Further tests
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showed that codeine was predominantly converted into morphine by this brain-specific
variant, while the major metabolite of human liver CYP2D6 is an inactive chemical
called nor-codeine. These results demonstrated the existence of a pathway, distinct from
known pathways in the liver, which may contribute to a number of drug interactions that
are of potential clinical importance for neurological diseases.

To obtain cDNA of this unique variant, we tried different techniques. First, we tried
to screen and clone this variant from the cDNA library of human brain substantia nigra,
and no positive clone has been probed. Second, we tried to amplify this variant by RTPCR from freshly isolated messenger RNA from human brain tissues. Several PCR
products were obtained. However, DNA sequencing analysis showed that these fragments
do not share any homolog to CYP2D family (data not shown). Third, we tried to construct
this CYP2D7 variant based on CYP2D6*1 cDNA sequence by site-directed mutagenesis
and insertion. After many cycles mutation followed by an insertion of extra 57 bp DNA
fragment, we successfully obtained the full-length cDNA of CYP2D7 variant. DNA
sequencing and alignment analysis indicated that the predicted amino acids of the
constructed CYP2D7 variant were 100% identical to the brain CYP2D7 variant. Western
blot showed that CYP2D7 variant reacted to both polyclonal and monoclonal antibodies
against CYP2D6. These results are consistent to the high identity between CYP2D6 and
CYP2D7 variant. The detected molecular weight is about 57kD that is the same as
previously reported (36).
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In this study, CYP2D7 variant exhibited Soret maxima at 450 nm based on carbon
monoxide difference spectral analysis. However, it also showed a strong absorbance at
420 nm. This phenomenon was observed in different P450 enzymes. It has been reported
that the enzymes at P420 are the inactive form of P450, which are deficient in the
catalytic activity of P450 (21, 34). Many investigators have reported that the inactive
form could be converted to the catalytically active form by treatment with sulfhydryl
compounds such as cysteine, thioglycolic acid, -mercaptoethanol, or dithioerythritol
(47). In order to increase the active form of CYP2D7 variant, cysteine was added in the
cell culture (Final concentration is 50 µg/ml). However, the ratio between these two
forms remained the same after the treatment (data not show), which implied that cysteine
could not convert the inactive form of CYP2D7 variant to the active form in the
expression system mediated by baculovirus.

Heme and -ALA are two commonly used resources for providing Fe3+ to P450
enzymes. -ALA is a heme precursor, and it can be converted to heme by a biosynthesis
pathway catalyzed by eight different enzymes such as ALA synthase and protophorphyrinogen oxidase. Among those enzymes, the first and the last three enzymes in this
pathway are located in mitochondria of different cells. In this study, no catalytic activity
was observed based on CO-reduce difference spectral analysis when Heme was used.
Instead, the activity of CYP2D7 variant was restored when -ALA was added into the
culture medium. Previous studies showed that the incorporation of heme into the catalytic
domain is probably one of the critical steps in the folding process of P450 enzymes.
Compared to heme, -ALA is more soluble and stable. It could promote the correct
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folding of P450 enzymes by increasing the availability of heme in E. coli expression
system by using -ALA (25).

The hepatic CYP2D6 primarily locates at microsome fraction. However, CYP2D6
was also found in plasma membrane, mitochondria and other intracellular membranes(18,
27, 31, 40). In brain tissues, several forms of P450 were found in mitochondrial
membranes (1, 2, 29, 43). In this study, Western-blot analysis indicated that CYP2D7
variant was predominantly present in the mitochondrial fraction of insect cells. This
results is consistent with CO-reduce difference spectra analysis of microsome fraction, in
which no activity was observed. Instead, the activity was observed in the mitochondrial
fraction. This result implied that human brain CYP2D7 variant probably has a unique
tissue target and plays very unique physiological and pathological roles in the human
brain.

Nonfunctional CYP2D6 genotypes have great impacts on the metabolism of drugs.
For example, codeine and its analogues are commonly prescribed drug for the treatment
of patients with chronic pain (3, 44). Codeine is converted to morphine by CYP2D6,
which is effective form. These drugs will be completely ineffective if the patients are the
poor metabolizers. Therefore, it is very important to identify the CYP2D6 genotypes of
patients. In this study, it was found that the brain variant CYP2D7 could metabolite
codeine to morphine with higher efficiency than CYP2D6. It is probably responsible for
the metabolism of drugs targeting human brain. Thus, whether this type of CYP2D7
variant is present in patients may have great influence on the metabolism of these drugs

91

in human brain. However, the specific substrates for this variant have not been
characterized yet.

Both p-tyramine and m-tyramine can be metabolized to dopamine by CYP2D6 (17).
The Km values of CYP2D6, for p-tyramine and m-tyramine were 190.1±19.5 microM
and 58.2±13.8 microM, respectively. Because the affinity between 2D6 and m-tyramine
is higher than that between 2D6 and p-tyramine, m-tyramine was selected for kinetic
analysis. In this study, it was found that the constructed CYP2D7 variant is probably
capable of metabolizing m-tyramine to dopamine (Figure 7c). However, dopamine was
also present in the negative control (Figure 7b). Ottaviani also has found that insect cells
were able to metabolize and/or detoxify dopamine-derived catecholic TIQs (dopaminederived tetrahydro-isoquinoline) (35). These observations implied that unknown enzymes
present in the insect cells could also metabolize m-tyramine to dopamine. In the current
study, the mitochondria fraction from insect cells can metabolize more m-tyramine to
dopamine than the mitochondria fraction from insect cells expressing 2D7 variant based
on the area under the curves, the probability is that the expression of these enzymes that
can metabolize m-tyramine to dopamine are limited in insect cells expressing 2D7
variant. For the future study, the purified enzyme or the enzyme expressed in different
systems will help us to confirm that if the constructed CYP2D7 variant is able to
metabolize m-tyramine to dopamine.

In the brain, MPTP is oxidized by mitochondrial monoamine oxidase to the active 1mithyl-4-phenylpyridinium ion (MPP+), which is selectively toxic to cells of the
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substantia nigra (26) – the region of the brain affected in Parkinson’s disease. In-vitro
studies have shown that MPTP and MPP+ may be metabolized by CYP2D6 (10) (5, 12)
which is localized to this region of the brain (32). Boopathi et al indicated that in rat
brains, CYP1A1 in the microsomes and mitochondria follow different kinetic patterns.
Under chronic BNF (- naphthoflavone) treatment conditions both in rat brain and
cultured C6 glioma cells, the mitochondria form continued to accumulate and become a
major part of the total 1A1 pool and exhibited high N-demethylation activity with a
variety of antidepressant and antinvulsant drugs (2). In our study, the CYP2D7 variant
was predominantly present in the mitochondrial fraction from the transfected insect cells.
This result indicated that the human brain CYP2D7 variant may have unique tissue
targets and play important physiological or pathological roles. For these reasons,
although it is not clear that what kinds of neuroactive drugs can be metabolized by
CYP2D7 variant, it is very important that individuals with 2D7 variant should be
considerate in the proper selection of drugs as well as determining the drug dose.

The brain’s defense against MPTP and similar compounds is the system of monooxygenases associated with cytochrome P450, particularly the subset CYP2D6 (6, 26).
In theory, individuals that have deficit CYP2D6 protein are at increased risk of
Parkinson’s disease because they have no defense against neurotoxins such as MPTP. In
current study, it was shown that brain CYP2D7 variant was unable to metabolite MPTP,
and a more probable role for the splice variant is the posttranscriptional down-regulation
of the expression of CYP2D6. The individuals with CYP2D7 variant may have poor
protection against MPTP neurotoxins and result in greater risk of Parkinson’s disease
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than individuals without this genotype. In addition, alternative splicing variant CYP2D7
can convert non-active form of drug into active one within target tissue brain, it may
contribute to a better understanding of the potential clinical importance for central
nervous system diseases.

Both Asp301 and Glu216 are important for CYP2D6 for the metabolism of basic
substrates (23). Investigation into the relationship between Asp301 and Glu216containing system suggests that both residues are necessary for metabolism of a basic
substrate. If either residue is missing then the specificity of the enzyme is altered.
Although both residues appear necessary for the metabolism of basic substrates, Glu216
does not replace Asp301 in the binding of basic substrates. There is an accepted model
for binding of MPTP by formation of an ion pair of the protonated amine with the
carboxylate anion of Asp301 in the enzyme active site and subsequent oxidation at a
distant site of the molecule. In 2D7 variant sequence, Asp301 is replaced by Asn, Glu216
is not been changed. Because Glu216 does not replace Asp301 in the binding of basic
substrates, substitution of Asp301 in 2D7 variant sequence may affect MPTP
metabolism. Previous study indicated that Phe120 contributed to determining the
specificity of substrate oxidation by CYP2D6(9), while in 2D7 sequence, residue Phe120
is replaced by Ile, this may affect the substrate orientation. The substitutions of D301N
and F120I may be one of the reasons that constructed 2D7 variant cannot metabolize
MPTP. It is important to take into account the influential role of D301N and F120I in
2D7 sequence in terms of characterizing 2D7 variant enzyme efficiency.
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In summary, the understanding of this unique CYP2D7 variant is still on the early
stage since this unique variant has only been found in the part of Indian population (36).
A functional CYP2D7 transcript has not been observed in other population such as Asian,
Caucasian and African American populations (11). In addition, our results were unable to
confirm Pai’s study based on the analysis of the constructed CYP2D7.

Figure legends
Figure 1
Alignment of CYP2D6 and CYP2D7. amino acid sequence alignment between
CYP2D6 and CYP2D7. In addition to 19 extra amino acids (57bps) in CYP2D7, the
different amino acids between CYP2D6 and CYP2D7 are indicated.
Figure 2
Construction and expression of brain variant CYP2D7 based on CYP2D6. (a) The
pFastBac I with 2D7 gene and 2D6 gene was transformed into DH10Bac competent cells,
these cells contain bacmid DNA. Recombinant bacmid DNAs can be obtained after
homologious recombination. The recombinant bacmid DNAs were confirmed by PCR.
The forward primer is 2D6 5’that can bind to 2D6 gene, the reverse primer is M13
reverse that can bind to bacmid DNA. The size of PCR product of 2D6 is 2074bps, and
the size of PCR product of 2D7 is 2131 bps. (b) Western blot analysis of CYP2D7
variant protein expression. CYP2D7 gene was expressed in insect cell line. The T. ni
whole cell lyses were loaded in SDS-PAGE gel, then proteins were transferred into
PVDF membrane. CYP2D6 monoclonal antibody was used for western blot. The
molecular weight of CYP2D7 is around 57.7 KD.
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Figure 3
Carbon monoxide difference spectroscopy of CYP2D7 variant. Spectra were
determined by the method of Omura and Sato (1964). The reduced carbon monoxide
difference spectra of the expressed protein exhibited Soret maxima at 454 nm
characteristic of P450. It also showed absorbance at 418 nm.

Figure 4
Analysis of CYP2D7 protein expression in different subcellular fraction by western
blot. Constructed CYP2D7 variant was over-expressed in T.ni insect cells using
baculovirus expression system. Different cell fractions were obtained according to
different centrifugation and time. Mitochondria and microsomes were isolated separately.
Both these fractions were analysed by western blot using anti-CYP2D6 monoclonal
antibody. Lane 1: insect cells; lane 2: cell lyses with CYP2D6; lane3: cell lyses with
CYP2D7 variant; lane4: CYP2D7 (microsomes); lane5: CYP2D7 (mitochondria); lane6:
purified CYP2D6 enzyme.

Figure 5
Codeine metabolism by constructed CYP2D7 variant. Codeine and its two
metabolites, morphine and nor-codeine, were separated by different retention time by
HPLC (Figure 5a). HPLC separation of codeine and its metabolites morphine and norcodeine by CYP2D7 variant with retention times of 7.668 min (morphine), 11.379 min
(nor-codeine) and 13.648 min (codeine) (Figure 5b).
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Figure 6
M-tyramine metabolism by constructed CYP2D7 variant. M-tyramine and its
metabolite dopamine were separated by different retention time by HPLC (Figure 6a).
HPLC separation of m-tyramine and its metabolite dopamine by CYP2D7 variant was
carried out by different retention times of 4.183(dopamine), 8.434 (m-tyramine) (Figure
6b). HPLC separation of m-tyramine and its metabolite dopamine by mitochondria
fraction from insect cells was done by different retention times of 3.978 (dopamine),
7.482 (m-tyramine) (Figure 6c).

Figure 7
MS analysis of dopamine formed from m-tyramine by constructed CYP2D7 variant.
Dopamine formation from m-tyramine was determined by ESI-MS. The m/z of dopamine
is 149.3. For m-tyramine metabolism, the reaction mixture was diluted in 50% methanol
and 50% acetonitrile to the final concentration of 1 µg/ml just before analysis. (a)
Standard; (b) m-tyramine metabolized by the mitochondrial fraction from the T. ni insect
cells; (c) m-tyramine metabolized by the mitochondrial fraction from the T. ni cells
expressing CYP2D7 variant
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Mutations

Primer sequences

V11M

5’-CCCCTGGCCATGATAGTGGCC-3’

R26H

5’-ATGCACCGGCACCAACGCTGG-3’

S70N

5’-GACGTGTTCAACCTGCAGCTG-3’

F120I, A122S

5’-CCAAGGGGTGATCCTGTCGCGCTATGGG-3’

N166D, H167Q, S168A

5’-GCCGCCTTCGCCGACCAGGCCGGACGCCCC-

L231P

5’-CCCCGTCCTCCCGCATATCCCAG-3’

Q258H

5’-CTAACTGAGCACAGGATGACCTGG-3’

P325L

5’-GATCCTACATCTGGATGTGCAGCG-3’

A351V, C355Y

5’-GGTGACCAGGTTCACATCCCTA
CACCACTGCC-3’

M374V

5’-GGGGACATCGTCCCCCTGGGTGT
GACCCATATG-3’

P469A, T470A

5’-GCTTCTCGGTGGCCGCTGGACAGCCCC-3’

L91M, H94R

5’-GGCTGGCGGCCGCGCGCGCCGCCATGGT
GACCCGCGGCGAGGAC-3’

V104A, T107Y, I109V

5’-CGCCCGCCTGCGCCCATCTACCAGGTCCT
GGGTTTCG-3’

E278K, M279K, N285S

5’-GGCCTTCCTGGCAAAGAAGGAGAAGGCC
AAGGGGAGCCCTGAGAGC-3’

A300G, D301N, S304L

5’-GCATAGTGGTGGGTAACCTGTTCCTTGCC
GGGATGG-3’

H478S, G479R, F481A
A482S, S486T

5’-GGCCCAGCCACTCTCGTGTCGTTTCTTTC
CTGGTGACCCCATCCCCC-3’

Table1. Primers for site-directed mutagenesis
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Figure 5 (b) Metabolism of codeine by CYP2D7 variant

108

tyramine
dopamine

Figure 6(a) Standard of dopamine and tyramine
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Figure 6 (b) Metabolism of Tyramine by CYP2D7 variant

110

tyramine

dopamine

Figure 6 (c) Metabolism of Tyramine by mitochondrial fraction
from T. ni insect cells
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Figure 7(a) Standard of dopamine
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dopamine

Figure 7(b) Tyramine treated with mitochondrial fraction
from T. ni cells
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dopamine

Figure 7(c) Tyramine treated with the mitochondrial fraction
from T. ni cells expressing CYP2D7
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Table 2. Kinetics of m-tyramine and codeine metabolism by CYP2D7
and CYP2D6

Amount of Dopamine
(pmol)

m-tyramine

Velocity (V0)

2D6*1

72.2

7.2

2D7

40.0

2.0

(500 µm)

Amount of Morphine
(pmol)

Codeine

Velocity (V0)

2D6*1

24.0

0.53

2D7

37.0

1.23

(2000µm)
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Abstract

CYP2D6 polymorphism has been associated with various human cancer
susceptibilities including lung cancer, breast cancer, skin cancer, bladder cancer, liver
cancer and prostate cancer. Except for liver CYP2D6, the genotype and function of these
extrahepatic CYP2D6 are still unknown. CYP2D alternatively splicing variants have been
found in liver and extrahepatic tissues. However, these splicing variants are minor forms in
liver. The factors required for tissue-selective expression of CYP2D splice variants are
unknown. It has hypothesized that the existence of these alternatively splicing variants may
impact the expression and functions of CYP2D6 in extrahepatic tissues, and the alternation
of CYP2D6 might play an important role in determining cancer risk.

The objective of this study is to test the genotype and function of CYP2D6 or
CYP2D variants in different human tissues including liver, brain, skin, eye and prostate. To
achieve this goal, a human brain cDNA library was screened by using CYP2D6 as a probe.
However, no positive clone has been found. Next, the sequence of CYP2D6 was used as a
query to search the EST library of these tissues, and five clones were found to be homologs
of CYP2D6. These five clones were amplified, and the insert cDNAs were further
sequenced. The results indicated that the clone from brain did not share any homolog to
CYP2D. As expected, the clone from liver was identical to CYP2D6. Interestingly, the
clones from eye, skin and prostate shared very high identify (99%) to the recently
identified brain variant CYP2D7, but a part of exon 6 (91bp) and the adjacent extra 57bp
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from intron 6 in CYP2D7 variant are absent in these clones. Sequencing analysis indicated
that these alternative splicing transcripts can not translate to full length due to the deletion
of a part of exon 6. To further confirm the sequencing analysis, the full-length skin
CYP2D6 variant was created and expressed by using a baculovirus expression system.
Western blot analysis showed that a 27kD truncated protein was detected, which is
consistent with the sequencing analysis. Except for the CYP2D7 variant in brain, several
other alternative splicing CYP2D variants have been identified in the different tissues of
human. However, none of them have been shown to be functional and process P450
activity (7). Nevertheless, the existence of these variants might cause the
posttranscriptional down-regulation of the expression of CYP2D6, further influencing the
physiological or pathological functions of CYP2D6 in these tissues.

Introduction

Alternative splicing of pre-mRNA has been reported to be not only involved in
regulating gene expression both quantitatively and qualitatively (25) but also specifically
and developmentally regulating many human gene expression in different tissues.
Likewise, it was found that alternative splicing also occurred among CYP2D genes (8, 11).
The CYP2D subfamily includes CYP2D6, CYP2D7 and CYP2D8P at the CYP2D locus,
and these three genes share 92 to 97% identity (9, 15). CYP2D8P was found to be a
pseudogene since there is a frame shift mutation and a stop codon within its exons, while
the CYP2D7 gene was found to have an insertion in its first exon that disrupts the reading
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frame of the protein (15). The alternative splicing of these genes result in different variants.
These variants include a (intron 5 included); b (intron 6 included); b’ (3’ portion of exon 6
deleted); c (exon 6 deleted); d (3’ 57-bp portion of intron 6 included); e (3’ portion of exon
6 deleted, 3’ 57-bp potion of intron 6 included) (12, 31). These variants are mainly found
in extrahepatic tissues such as brain, lung, breast and other tissues (7, 8, 12, 13).

There are at least five alternatively spliced CYP2D transcripts have been reported in
brain tissues: the most commonly found transcript was c variant, followed by b’ and the
wild type, the b, d and e transcripts were the least abundant (7, 31); A full-length mRNA
and variant c, b’, e, d and b were detected in human breast tissues (29). Full-length mRNA
was a minor form whereas variants b’ and c predominated. The messenger RNA of CYP2D
was not only probed in the normal tissues, but also detected in the cancer tissues such as
breast, lung and prostate cancers (13, 14, 17, 23, 29). The functions of CYP2D6 and its
variants in these tissues are still unknown in terms of the metabolism of drugs and toxins,
pathogenesis and carcinogenesis. In brain, defects in the CYP2D6 gene have been
associated with a number of CNS diseases such as Parkinson’s disease (1, 6, 16, 26),
Alzheimer’s disease (28), neuroleptic-induced disorders such as tardive dyskinesia (19)
and certain types of CNS cancer (3, 32). In skin, it was shown that mutant alleles (e.g.
CYP2D6*4) are associated with increased susceptibility to malignant melanoma and basal
cell carcinomas (22, 27). The allelic variants of the CYP2D6 gene have also been
implicated in susceptibility to lung and breast carcinogenesis (2, 30). However, the types
of variants in these tissues have not been characterized yet. No functional CYP2D enzymes
have been obtained from these tissues with the exception of brain, in which a functional
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CYP2D7 variant has recently been identified in Indian population (20). These limitations
have hampered the investigation of the physiological and pathological roles of CYP2D in
these extrahepatic tissues. To detect whether a functional CYP2D6 or variants are present
in these extrahepatic tissues, human brain cDNA libraries and the EST libraies of these
tissues were probed by using CYP2D6. No positive clones were identified in the human
brain cDNA libraries examined. However, several positive clones were obtained from EST
libraries and sequenced. A full-length skin variant was constructed and further expressed in
a T. ni insect cell line mediated by baculovirus.

Materials and Methods
Human brain cDNA library and the clones from EST libraries: A human
substantia nigra cDNA library was bought from Stratagene (Cat# 936210). Human eye
EST clones (EST number: UI-E-EJ0-AIM-I-13-0-UI.S1 and UI-E-EJ0-AIN-J-13-0UI.R1) were bought from OPEN Biosystems. A human liver cDNA clone (EST number:
602614603F1), a prostate cDNA clone (EST number: 602650030F1) and a skin cDNA
clone (EST number: 602634230F1) were bought from Invitrogen.

Labeling of CYP2D6 with DIG labeled probe: The full-length CYP2D6 DNA was
obtained by PCR amplification from plasmid pFB2D6*1 (18, 34). The resultant PCR
product was purified by PCR Purification Kit (Qiagen). 100_g purified PCR product was
denatured with alkaline followed by purification with ethanol. The CYP2D6 probe was
labeled with digoxigenin-dUTP by using a DIG Labeling and Detection Kit (Roche,
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Indianapolis) following manufacture’s recommendation. The digoxigenin-dUTP was
incorporated into CYP2D6 DNA by using random primed DNA labeling. A 15_l of DNA
(3_g) was mixed with Hexanucleotide 2_l, dNTP 2_l and Klenow enzyme 1_l, and
mixture was incubated at 37˚C for 6 hours. The labeled probe was further purified by
using a Nucleotide Removing Kit (Qiagen) to remove free digoxigenin-dUTP. The
resultant probe was quantified according to the manufacture’s recommendation. The
probe was detected with Anti-Digoxigenin-AP Detection Kit (Roche). The sensitivity of
labeled probe was detected by dot-blot.

Screening of human brain cDNA library: A standard procedure was used to screen
the human brain cDNA library from substantia nigra. Briefly, a bacteriophage library was
first plated at about 30,000 - 50,000 pfu per 150 mm Petri dish by adding an appropriate
amount of bacteriophage in 500µl E. coli (A600 = 0.5) MgSO4-stored. Following 15
minute incubation at 37°C without shaking, the cells were plated with 7 ml LB top agar
on LB agar plates. Once the top agar has solidified, the plates were inverted and
incubated overnight at 37°C. The plates were cooled at 4°C for at least one hour to
prevent the top agar from lifting off the plate during the blotting process. A nitrocellulose
filter was slowly laid on the agar surface from the center to the side. The filters were
handled only by their edges with forceps. The position of filter on the plate was marked
by piercing the filter with a 25G needle dipped briefly in India ink in three
asymmetrically positioned spots per filter. Following the transferring, the nitrocellulose
the membranes were sequentially treated with the 1.5M NaCl and 0.5M NaOH for 2 min,
1.5M NaCl and 0.5M Tris.Cl (pH 8.0) for 5min, and 2xSSC (300mM sodium chloride, 30
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mM sodium citrate, pH 7.5) and 0.2M Tris.Cl (pH 7.5) for 5 min. The treated membranes
were dried on 3 mm Whatman paper at room temperature for 10 min.

For DNA hybridization, the membranes were put in hybridization bag that contains 5
ml standard hybridization buffer (1% blocking reagent, 0.1 M maleic acid, 0.15M NaCl,
pH7.5) and incubated at 68˚C for 1 hour. Following the incubation, the denatured DIGlabeled 2D6 probe was added into the bag and incubated at 65˚C for over 16 hours with
gentle agitation. After hybridization, the membranes were sequentially washed with the
following solutions: 2x SSC and 0.1% SDS for 5 min at room temperature for a total of 2
times, and 0.1x SSC and 0.1% SDS at 68˚C for 15 min for a total of 2 times washes.

For the detection, the membranes were first treated with maleic acid buffer (0.1 M
maleic acid, 0.15M NaCl, pH7.5) for 5 minutes, and then transferred into boxes
containing 20ml blocking solution followed by 30 minutes incubation. After incubation,
2.0_l anti-DIG-AP conjugate (1:4000) was added and incubated for 1 hour. Pouring off
the buffer, the membranes were first washed with 50 ml maleic acid buffer for 15 min for
2 times, and then rinsed with 20 ml Detection buffer (0.1 M Tris.Cl, 0.1 M NaCl, pH
9.5). Finally, pouring off buffer, the membranes were treated with 5 ml detection buffer
containing 30_l NBT solution and 17_l X- phosphate solution. The membranes were
incubated in dark room for 30 minutes to 12 hours.

Amplification of EST clones and DNA sequencing: The cDNA clones were
amplified in JM109 E. coli cells (Promega). Plasmids were purified with Mini-Plasmid
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Purification Kit (Promega). Standard primers (T7, M13F and M13R), which bind at the
flank region of inserted cDNA, were used for the double-stranded DNA sequencing
(Northwood DNA, Inc.). DNA homolog search were carried out with BLAST (NCBI).

Construction of full length human skin CYP2D cDNA: Full length skin CYP2D
cDNA was constructed by a two-step PCR process as shown in Figure 1. Briefly, Skin
CYP2D cDNA from ESTs was first amplified by PCR by using a pair of primers as
follows: Skin5’ (5’-GGCGC GAGCAGAGGCGCTTCT-3’) and skin3’ (5’-AAGCTT
GGAACTACCA CATTGCTT-3’). The wild type CYP2D6 fragment including exon
1and 2 was amplified by PCR by using the primers 2D6 5’ (5’-GGATTATTCATACC
GTCC-3’) and 2D6 3’ (5’-AGAAGCGCCTCTGCTCGCGCC-3’). The PCR thermocycling programs consisted of a three-step cycle repeated 30 times: denaturing at 95ºC for
1 min, annealing at 59ºC for 1 min, and extension at 72ºC for 1 min, followed by a finial
extension at 72ºC for 5 minutes. The full length skin CYP2D cDNA was amplified by
PCR by using the primers 2D65’ and skin 3’. The thermo-cycling programs are the same
with the exception of annealing at 62ºC for 1 min. An endonuclease restriction enzyme
cutting site (Hind III) (highlight in bold) was engineered in the primer skin 3’. The
resultant PCR product was cloned into PCR cloning vector pGEM-T (Promega). The
final construct was reconfirmed by DNA sequencing analysis.

Cloning the constructed CYP2D cDNA into baculovirus: The constructed skin
CYP2D gene was cut from the PCR cloning vector with Bam HI and Hind III. The
resultant fragment was cloned into the vector pFastBac (Invitrogen) to create the
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recombinant plasmid pFBCYP2D*S, which was further transformed into DH10Bac
competent cells (Invitrogen). After incubating on Luria agar plates for 24 to 48 hours at
37 °C, white clones which contain recombinant bacmid DNA were picked into LB
medium containing kanamycin (50_g/ml), gentamicin (7_g/ml) and tetracycline
(10_g/ml) and grow at 37 °C with shaking at 250 rpm overnight. A DNA purification
system (Promega) was used to isolate the recombinant bacmid DNA.

To create viral stocks, 9x105 T.ni cells per 35-mm (of a 6-well plate) was seeded at
27°C in 2 ml of SFX-INSECT (Hyclone) containing 10% fetal bovine serum, 100_g/ml
Penicillin-G, 60_g/ml Streptomycin sulfate, and 0.6_g/ml Amphoterecin-B.
GenePORTER TM reagent (Gene Therapy System) was used to accomplish the
transfection of T.ni cells with recombinant bacmid DNA. Recombinant virus was
harvested 72 hours post-transfection. Baculoviral stocks were amplified by subsequent
passages onto a new 100-mm dish of T.ni cells with 30 ml medium followed by
incubation for 7 to 8 days.

Protein expression and Western blot analysis: Infection was carried out at a cell
density of 1.6 to 2.0x106 cells/ml using 200µl of amplified viral supernatant. Heme (finial
concentration 4_g/ml) was added together with virus. Cells were harvested 3 to 4 days
post-infection, re-suspended and washed once in storage buffer (100mM potassium
phosphate, 20% glycerol, 0.33mM dithiothreitol, 1mM EDTA, pH 7.4). The cell pellets
were stored at -80 °C for further analyses. SDS-PAGE and Western-blotting with the
enhanced chemiluminescence detection method were carried out as the manufacture’s
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recommendation (Amersham Biosciences). Polyclonal and monoclonal antibodies
(Catalog NO.458246) against human CYP2D6 were purchased from BD GentestTM and
PANVERA. Briefly, identical amounts of proteins were loaded into each lane of a 10%
polyacrylamide gel. Following electrophoresis, the sample proteins were transferred to
PDVF membrane. The resultant blots were blocked in 5% fat-free milk at room
temperature for 1 hour, and then incubated in 2% milk containing primary antibodies for 1
hour at room temperature followed by three times wash by using T-PBS (0.15% Tween-20,
0.067 M phosphate-buffered saline, pH 7.5). The blots were developed by using
horseradish peroxidase-conjugated secondary antibody with the ECL luminal assay.

Results and Discussions

The screening of human brain cDNA library from substantia nigra. Previous
studies indicated that CYP2D6 RNA was detected in several regions of human brains and
the level of mRNA varied significantly among regions. The highest level was observed in
cerebellum and the lowest levels in putamen, globus pallidus and substantia nigra (18). In
the current study, human brain substantia nigra cDNA library was probed with CYP2D6.
Of the approximate 300 plaques present in each membrane, total of 24 membranes probed
with CYP2D6, no positive plaques were identified (Figure 2). Thus, no CYP2D cDNA
clones were screened from this library. This negative result may be explained by the
following reasons: First, the abundance of CYP2D cDNA is very low in the library of
human brain substantia nigra. Indeed, the mRNA of CYP2D6 was found to be the lowest
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in substantia nigra and putamen versus other brain regions (24). In future studies, cDNA
libraries from different parts of human brain including cerebellum should be used for
detection. Secondly, the sensitivity of labeled probe of CYP2D6 is about 100pg (Figure 1)
and this sensitivity which may not be enough to detect the cDNA of CYP2D6 from the
library. In the future, different labeling techniques can be used such as a radio-labeled
probe that is much sensitive than a DIG-labeled probe.

Sequencing analysis of CYP2D clones from EST libraries of human eye, liver,
prostate and skin. EST means “expressed sequence tags”. What they did was that they
isolated RNA from tissue, then using poly-A to do RT-PCR to get cDNAs, cloning these
cDNA into vectors. Usually they are just a few hundred base pairs at length. Currently,
there are many EST libraries from human tissues available. To detect if there are CYP2D
cDNA present in these libraries, the sequence of CYP2D6 was used as a query for
searching. Among them, five clones were found to share high identity to CYP2D6. Each
of these five clones was further confirmed by sequencing analysis. The results are
completely consistent the sequences present in the EST libraries, except for the clone
from the brain EST library, which did not share homology to the CYP2D genes (data not
shown).

As expected, the clone from liver is a partial cDNA of CYP2D6 (data not shown).
The clones from human eye, skin and prostate share the highest identity (99%) to a
recently identified human brain CYP2D7 variant (Figure 3). The human prostate cDNA
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clone contains exon 3 to 5, exon 6 with 91 bps deletion, exon 7 to exon 9. Human skin
cDNA clone contains exon 3 to 9, with 91 base pairs deletion in exon 6. The clone from
human eye only contained exons 7, 8, and 9 (Figure 3), and it is unknown if 91 base pairs
is deleted from the exon 6. These results indicate that the alternatively spliced variants do
exist in these tissues, and that the identified transcripts are probably caused by the
alternative splicing of CYP2D7. As noted, similar alternative splicing variants from
CYP2D7 have been identified from tissues such as liver and brain (7). Among those
variants, they only showed parts of CYP2D genes the genetic information in the rest part
of the genes is not available. Thus, it is hard to determine their genotypes and whether
these transcripts are translatable. Among those variants whose full-length cDNA
sequences have been decoded, none of them could be translated to functional proteins
except for the variant identified in Indian population (7, 20).

Construction and expression of human skin CYP2D variant. To experimentally
test whether these transcripts are translatable, the skin cDNA clone was chosen for
further analysis. As mentioned above, the skin cDNA contains only exons 3 to 9. It dose
not contain exon 1 and 2. To create the full-length cDNA, the exon 1 and 2 from
CYP2D6*1 were ligated to the 5’ end of the transcript by 2-Step PCR (Figure 4). The
first step PCR was used to respectively amplify exon 1 to 2 (352 bp) from CYP2D6 and
exon 3 to 9 (1,049 bp) from the skin clone (Figure 5). In the second step PCR, the above
PCR products were used as templates, and two fragments were ligated together. As
shown in Figure 5, the exon 1 and 2 were successfully ligated to the 5’ end of the
transcript and resulted in a 1,401bp PCR product. DNA sequencing analysis further
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confirmed that a presumably full-length skin cDNA was constructed, and that no
additional mutations were created during the PCR reactions. However, the gene
translation analysis indicated that the deletion of 91bp in exon 6 resulted in a frame shift
mutation, and the portion of the gene before this deletion is only able to translate to a 27
kD protein.

To further confirm this prediction, the full-length skin CYP2D was expressed in
insect cells by using a baculovirus-mediated expression system. The creation of high titer
baculovirus stock, the growth of baculovirus, the media conditions, the addition of heme,
the infection of T. ni cells with baculovirus were as described previously (34). The
expressed product was detected by Western-blot analysis with monoclonal antibodies
against CYP2D6. As shown in Figure 6, an approximately 50kD protein was detected in
the positive control (insect cells infected with baculovirus containing CYP2D6*1).
However, only a 27kD protein was found in insect cells infected with baculovirus
containing the skin CYP2D, indicating that a truncated protein was translated from the
constructed skin CYP2D. This result is consistent with the translational analysis, and
further confirmed that the identified human skin CYP2D could not be translated to a fulllength functional protein.

Due to the lack of crystal structure, Gotoh modeled the CYP2D6 structure based on
the similarity between CYP2D6 and P450 101 A (10). In this model, six separate regions
were tentatively assigned as substrate recognition sites (SRSs) in CYP2D6 , including B’
and flanking areas (103-126), the C-terminal end of Helix F (209-216), the N-terminal
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end of Helix G (248-255), the N-terminal half of Helix I (302-320), the 3 area (378-385)
and a central region of 5 (485-493). In addition, several functional residues have been
identified in terms of the drug-enzyme interaction. Residue Asp301 has been
characterized as being involved in electrostatic interactions with substrates on the basis of
homology modeling and site-directed mutagenesis (4). Residue Glu216 also plays an
important role in the binding of the basic nitrogen of CYP2D6 substrates (21). One recent
study indicated that Phe120, located on the B’-C loop, contributes to determining the
specificity of substrate oxidation by CYP2D6 (5). This skin variant encodes a 27kD
truncated protein that contains N-terminus 327 amino acids. It contains four substrate
recognition sites and all the functional residues mentioned above. Thus, this truncated
protein may still play important physiological or pathological roles in the skin tissue even
it lost the enzymatic activity of P450.

Huang et al. found that there were six different alternatively spliced forms of CYP2D
mRNA, including a full-length form, in human breast and lung tissues in the region of
exons 5-8 (12, 13). Woo et al. found that the CYP2D genes resulted in at least five
alternatively spliced transcripts in the human brain (31). Importantly, these brain CYP2D
variants are the same as the variants found in the breast and lung, albeit occur at different
frequency. Recently, several other variants were identified in human liver and human brain
(7). In this study, a variant from CYP2D7 with a deletion of part of exon 6 (91bp) was
found in skin and prostate. DNA sequencing and expressional analysis showed that this
variant could not be translated to a functional protein. Yengi found that CYP2D6 mRNA
levels was highest in skin, and thus there was significant inter-individual variation (over
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10-fold) (33). However, the genotypes and functions of CYP2D in human skin are still
unknown. It cannot be excluded that the existence of this splice variant has the
posttranscriptional down-regulation of the expression of CYP2D6, nor that a 27 kD protein
could serve a functional role.

Figure legends

Figure 1
CYP2D6 probe labeled with DIG. The CYP2D6 probe was labeled with digoxigenindUTP by using a DIG Labeling and Detection Kit following manufacture’s
recommendation. The sensitivity of labeled probe of CYP2D6 is about 100pg.

Figure 2
Human brain cDNA library screening. A human brain substantia nigra cDNA library
was probed with CYP2D6. The right panel shows the positive plaques used as a control.
The left panel shows the plaques present in the nitrocellulose membrane of the brain
library which was probed with CYP2D6.
Figure 3
EST clones amplification and DNA sequencing. The cDNA clones from ESTs were
amplified in JM109 E. coli cells. The commercial primers T7, M13F and M13R which
bind at the flank regions of inserted cDNA were used for double-stranded DNA
sequencing. DNA homology searches were carried out with BLAST. The clones from
human eye, skin and prostate share the highest identity (99%) to a recently identified

130

human brain CYP2D7 variant. The human prostate cDNA clone contains exons 3 to 5,
exon 6 with 91 bps deleted, and exon 7 to exon 9. The hman skin cDNA clone contains
exon 3 to 9, also with a 91 base-pair deletion in exon 6. The clone from human eye
contains exon 7, exon 8 and exon 9. The re-constructed human skin cDNA contains
exons 1 to 9 with the 91bp deletion in exon 6.

Figure 4
Full-length human skin CYP2D cDNA construction. Full length skin CYP2D cDNA
was constructed by two-step PCR. Skin CYP2D cDNA from ESTs and the wild type
CYP2D6 fragment including exon 1and 2 were amplified by the first PCR. The amplified
two fragments were ligated by the second PCR.

Figure 5
Full-length human skin CYP2D cDNA construction and amplification by PCR. Skin
CYP2D cDNA (from ESTs library) was first amplified by PCR by using a pair of
primers: (5’-GGCGC GAGCAGAGGCGCTTCT-3’) and (5’-AAGCTTGGAACTACCA
CATTGCTT-3’). The size of the resultly predicted PCR product is 352bps. The wild type
CYP2D6 fragment including exon 1and 2 was amplified by PCR by using the primers
2D6 5’ (5’-GGATTATTCATACCGTCC-3’) and 2D6 3’ (5’-AGAAGCGCCTCT
GCTCGCGCC-3’). The size of PCR product is 1049bps. The whole length skin CYP2D
cDNA was amplified by PCR by using the primers 2D65’ and skin 3’. The size of PCR
product is 1401bps.
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Figure 6
Western blot analysis of human skin CYP2D proein expression. Human skin CYP2D
was over-expressed in T.ni insect cells using baculovirus-mediated expression system.
The expressed proteins were separated by SDS-PAGE, and transferred onto PVDF
membrane. CYP2D6 monoclonal antibody was used for detection. An approximately
50kD CYP2D6 protein was detected from insect cells infected with baculovirus
containing CYP2D6*1. A 27kD protein was found in the insect cells infected with
baculovirus containing skin CYP2D.
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